The QualityStocks Daily Tuesday, October 27th, 2020

Today's Top 3 Investment Newsletters

QualityStocks (SFOR) +253.42%

MarketClub Analysis (SRRK) +1118.80%

CryptoCurrencyWire (CIIX) +43.56%

The QualityStocks Daily Stock List

Allied Corp. (ALID)

Stock Day Media, Cannabis Daily, Cannabis Business Times, Topshelf.news, Mugglehead, Stockopedia, Stockhouse, Tiingo, Nasdaq, MarketWatch, Morningstar, TradingView, Simply Wall St, ADVFN.com, GlobeNewswire, Newsfilecorp, The Globe and Mail, docoh, Stockwatch, Barchart, Market Screener, GuruFocus, Fintel, OTC Markets, Seeking Alpha, Finbox, Wallet Investor, CEO.ca, Investors Hangout, and EIN News reported earlier on Allied Corp. (ALID), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Allied Corp. is a global medical cannabis production company listed on the OTC Markets’ OTCQB. Its mission is to address contemporary medical issues through researching, creating, and producing targeted cannabinoid health solutions. The Company delivers an array of cannabinoid solutions for health and wellness applications, with an initial emphasis on Post Traumatic Stress Disorder (PTSD) or also known as Post Traumatic Stress Injury (PTSI). Allied has its corporate headquarters in Kelowna, British Columbia.

The Company uses an evidence-informed scientific approach to make its mission possible. It does so via pioneering pharmaceutical research and development (R&D), inventive plant-based production, and unique development of therapeutic products. The Four Pillars of the Company’s Model are: Production, Pharmaceutical, Natural Health, and the Allied Charitable Foundation.

Allied strategically takes advantage of an end-to-end business model. This model enables the Company to quickly identify where people most need help, isolate therapeutic strains to precisely address those unmet needs, and bring innovative and effective products to market with the help of its genetic specialists and doctors.

Along with its emphasis on PTSI, Allied’s R&D department is also presently identifying and initiating work on a number of other medical issues, which have major impact on individual sufferers and society as a whole. In essence, the Company assembles the team of experts needed. This is from molecular biologists to geneticists, doctors, medical professionals and science-based growing specialists – to produce strains that target today’s health needs with precision and efficacy.

In mid-October, Allied announced it signed its first monthly recurring purchase order. It announced the signing of its first monthly recurring forward purchase agreement with Mistral Consulting Group for the sale of Allied’s proprietary cannabis products. This agreement comprises a monthly recurring purchase order of extracted cannabis products in quantities scaling from 1-5kgs per month to 50kgs per month for each month between November 2020 and March 2021.

In addition, this month, Allied announced the filing of a new United States provisional patent application entitled “Psilocybin Compositions And Formulations And Their Use In Treating Mental Health Disorders And Improving Mental Health”. The provisional patent application covers a novel combination of psilocybin and proprietary mushroom formulation, and also a novel treatment regimen targeting Post Traumatic Stress (PTSD), Depression, and General Anxiety.

Calum Hughes, Chief Executive Officer of Allied, said, “Adding the psilocybin pharmaceutical product leverages our clinical trial expertise and infrastructure while simultaneously broadening our product offering beyond cannabis. With this provisional patent application, we have deepened our pharmaceutical pipeline in our key therapeutic areas of PTSD, Depression and General Anxiety.”

Allied Corp. (ALID), closed Tuesday's trading session at $1.90, up 26.6667%, on 939 volume with 7 trades. The average volume for the last 3 months is 8,970 and the stock's 52-week low/high is $1.00/$4.50.

Amfil Technologies, Inc. (FUNN)

Financial Buzz, TableTopWire, Simply Wall St, OTC Markets, TipRanks, Micro Cap Daily, StockNewsUnion, Macroaxis, InvestorsHub, Street Insider, CRWE World, GlobeNewswire, Infront Analytics, Morningstar, Insider Financial, Dividend Investor, Stockopedia, MMJ Reporter, Dividend.com, GuruFocus, Investors Hangout, Barchart, wallstreet-online, FX Empire, Nasdaq, Stockwatch, and New Media Wire reported beforehand on Amfil Technologies, Inc. (FUNN), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Amfil Technologies, Inc. concentrates chiefly on the acquisition of income generating private companies and optimizing their operations under the Amfil Technologies umbrella. The Company’s focus is on growing shareholder value through allowing investors access to self-sustaining small to medium sized businesses with proven profitable strategies, and identified as having considerable potential for future growth. Amfil Technologies is headquartered in Markham, Ontario.

Amfil mainly invests in small to mid-sized companies with above average service capacity, growth potential or existing market share. The Company works to achieve long-term financial returns consisting of regular dividend income, benefiting from preferential tax treatment, and expecting modest mid-to-long term capital growth.

Amfil Technologies is the operator of three businesses. One is Snakes & Lattes, Inc. This is a board game bar/cafe and board game retailer/distributor/publisher. Snakes & Lagers and Snakes & Lattes are the operators of board game themed bars and cafes. Snakes & Lagers holds the trade name and is the owner of Snakes & Lattes, which currently operates three tabletop gaming bars and cafes in Toronto and one in Tempe, Arizona. The Company is in the process of expanding across North America.

Another Amfil business is Interloc-Kings, Inc. This is a hardscape construction company based in southern Ontario. Interloc-Kings is an established hardscape construction and winter services provider to the Greater Toronto area & York Region, in the Province of Ontario. This subsidiary is an authorized Unilock installer. Unilock is North America's premier manufacturer of concrete interlocking paving stones and segmental wall products.

Another Amfil business is the EcoPr03 GRO3 Antimicrobial System. The EcoPr03 GRO3 Antimicrobial System was jointly developed between Amfil Technologies and A.C.T.S., Inc. This system is a triple-function sanitization unit capable of naturally eliminating 99.9 percent of water and airborne pathogens and the normally problematic pests, which cause havoc for cultivators, as well as bacteria, fungus, microbes, and mold on surfaces, all without chemicals.

Last month, Amfil Technologies announced that it will be entering the cannabis dispensary business starting with an initial pre-vetted retail location, then 4-5 additional locations in Southern Ontario, and ultimately plans to expand its reach throughout Canada, the United States, and potentially Central and South America. Amfil has partnered with experienced and licensed cannabis dispensary operator, Mr. David Berkovits, to create and manage operations for Amfil’s new cannabis dispensary division. Mr. Berkovits is a licensed dispensary operator. He will be managing the license application process for the Company after recently successfully obtaining the license for himself in Canada.

Furthermore, in September, Amfil Technologies announced it purchased the Chicago Board Game Café. It reopened it on October 14, 2020 under the name Snakes & Lattes Chicago. The café is located at 1965 N. Milwaukee Ave. in Logan Square (known as the Margie’s Candies building). It will be Snakes & Lattes’ seventh and largest location. Reservations are required because of COVID-19.

Amfil Technologies, Inc. (FUNN), closed Tuesday's trading session at $0.0178, up 4.0936%, on 631,676 volume with 10 trades. The average volume for the last 3 months is 583,789 and the stock's 52-week low/high is $0.006949999/$0.090899996.

Conversion Labs, Inc. (CVLBD)

Zacks, TipRanks, MarketWatch, Investing.com, Stock Day Media, Nasdaq, InvestorsHub, Market Screener, GuruFocus, Dividend Investor, Stockopedia, last10k, Finbox, FX Empire, Stockhouse, Equity Clock, Morningstar, MarketBeat, Seeking Alpha, OTC Markets, The Globe and Mail, TMXmoney, MacroTrends, Simply Wall St, Barchart, Wallet Investor, Proactive Investors, docoh, YCharts, PR Newswire, Digital Journal, GlobeNewswire, and Investors Hangout reported beforehand on Conversion Labs, Inc. (CVLBD), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Conversion Labs, Inc. is a direct-to-consumer telemedicine and wellness company. It has a portfolio of online direct-to-consumer brands. The Company’s PDFSimpli subsidiary is a Software-as-a-Service (SaaS), which permits users to convert, edit, sign, and share PDF documents online. The Company formerly went by the name Immudyne, Inc. It changed its corporate name to Conversion Labs, Inc. in June of 2018. Incorporated in 1987, Conversion Labs is headquartered in New York, New York. The Company’s shares trade on the OTC Markets Group’s OTCQB.

Conversion Labs’ brands combine virtual medical treatment with prescription medications and unique Over-the-Counter (OTC) products. The Company’s network of licensed physicians provides telemedicine services and direct-to-consumer pharmacy to consumers across the USA. Concerning its emphasis on changing healthcare, Conversion Labs is applying its direct response marketing expertise to healthcare. It is centering on providing a convenient, cost-effective, and smarter way for consumers to access high quality OTC products and prescription medications.

Conversion Labs’ brands include Shapiro MD. This brand features personalized treatment plans for male and female hair loss. Another brand is iNR Wellness MD - a "super-food" for immune system support. In addition, the Rex MD brand is E.D. (erectile dysfunction) meds prescribed and shipped discreetly to the consumer. Moreover, the SOS RX brand is prescription medications for disaster scenarios.

Last week, Conversion Labs announced it appointed healthcare veteran, Dr. Connie Mariano, to its Board Of Directors. Following her appointment, the Board will have eight members, with five serving independently.

Dr. Mariano is Board certified in internal medicine. She brings three decades of executive leadership in healthcare to Conversion Labs. She will advise Company Management on health care services and product development related to Conversion Labs’ telemedicine brands. This includes Rex MD™, Shapiro MD™, SOS Rx™, Veritas MD™, as well as others under development.

Yesterday, Conversion Labs announced it signed a licensing agreement with Restorsea, a foremost medical grade skincare technology platform. Conversion Labs’ plan is to use Restorsea’s intellectual property (IP) and proprietary formulations to create a best-in-class clinical-grade over-the-counter (OTC) skincare line to be marketed under the new Nava MD™ brand. It plans to launch Nava MD in Q1 of 2021.

Conversion Labs, Inc. (CVLBD), closed Tuesday's trading session at $6.49, up 5.5285%, on 22,855 volume with 100 trades. The average volume for the last 3 months is 117,700 and the stock's 52-week low/high is $0.50/$10.6999998.

Izotropic Corporation (IZOZF)

WallStreetNation, Healthcare Global, TheNewswire, OTC Markets, Nasdaq, Stockwatch, Stockhouse, MarketWatch, GuruFocus, Dividned.com, Mining Stock Education, InvestorsHub, Investing News, Investor Intel, Wallet Investor, TradingView, Financial Buzz, TipRanks, Macroaxis, Morningstar, CEO.ca, The Globe and Mail, Newsfilecorp, Seeking Alpha, Dividend Investor, Market Screener, Barchart, IRW Press, Simply Wall St and Stockopedia reported earlier on Izotropic Corporation (IZOZF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Izotropic Corporation and its wholly-owned U.S. operating subsidiary, Izotropic Imaging Corp. were created to commercialize the next generation of breast imaging technology for early diagnosis of breast cancer. It has the exclusive global license from the University of California, Davis to commercialize the technology developed by principal Founder and Company Director Dr. John M. Boone and researchers at UC Davis. Incorporated in 2016, Izotropic has its corporate headquarters in Surrey, British Columbia. The Company lists on the OTC Markets.

Roughly $20 million in research funding and more than 15 years of research and development (R&D) have been invested in developing this pioneering breast CT imaging technology. Research includes a current, continuing $2.9M U.S. clinical trial at UC Davis Medical Center. The above-mentioned license includes all intellectual property (IP), trade secrets, patents, and patent-pending applications, which are the foundation of the Izotropic 's breast CT imaging platform.

The Izotropic Breast CT Imaging System produces high resolution breast images in 3D. A single 10 second breast CT scan acquires about 500 images. This is without painful breast compression. This provides radiologists with fully 3D viewing of the scanned breast.

In late September, Izotropic announced that its Executive and Scientific Advisory Teams were to meet with the U.S. Food and Drug Administration (FDA) on October 20, 2020. Izotropic filed a Pre-Submission Application with the FDA that began the market approval process for the Company's commercial Breast CT Imaging System. The next step in this process is the Pre-Submission meeting where Izotropic will present and obtain feedback from the FDA on product and indication for use statements, device labelling terms, future marketing claims, and also study designs.

Last week, Izotropic announced a non-brokered private placement financing of up to 6,000,000 units of the Company at a price of $0.55 per Unit for gross proceeds of up to $3,300,000. The use of proceeds from the Offering will be used for final engineering and product development of Izotropic’s first commercial breast CT unit; production of commercial units; the initial FDA study; as well as general working capital.

Izotropic Corporation (IZOZF), closed Tuesday's trading session at $0.9691, off by 6.1768%, on 54,348 volume with 40 trades. The average volume for the last 3 months is 34,584 and the stock's 52-week low/high is $0.081430003/$0.854200005.

Obsidian Energy Ltd. (OBELF)

Ask Finny, Zacks, MarketWatch, FX Empire, Stockhouse, Wallmine, Market Screener, OTC Markets, Wallet Investor, TradingView, Dividend Investor, Morningstar, Stockzoa, Trade Ideas, Barchart, YCharts, MacroTrends, Nasdaq, CamTrader, GuruFocus, InvestorsHub, Stockwatch, PR Newswire, Business Insider, Whale Wisdom, Stock Analysis, Seeking Alpha, Dividend.com, and Webull reported previously on Obsidian Energy Ltd. (OBELF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Obsidian Energy Ltd. is an intermediate-sized oil and gas producer based in Calgary, Alberta. It has a well-balanced portfolio of high-quality assets producing about 30,000 boe per day. The Company was formerly known as Penn West Petroleum Ltd. It changed its corporate name to Obsidian Energy Ltd. in June of 2017. The Company’s shares trade on the OTC Markets Group’s OTCQX.

Obsidian Energy has high quality assets and a large acreage position. It is the largest acreage holder in the Cardium. The Cardium is one of Canada’s lowest cost light oil resources, with strong IRR (Internal Rate of Return) and recycle ratios. Recent work added has increased the Company’s inventory to greater than 900 gross Cardium locations.

Obsidian Energy has had strong well performance since the beginning of 2018 in the Willesden Green Cardium (Crimson Lake and East Crimson). All 10 wells in the H1 2020 program were on production. Obsidian has ownership and control of strategic infrastructure. This includes pipelines, processing, and compression facilities. Additionally, it has the ability to grow near-term production in Willesden Green and Pembina with minimal infrastructure spend.

The Company’s Crimson Lake had Q2 2020 average production of 10,134 boe/d. It is the Obsidian Energy cornerstone for revitalized primary development on its Cardium acreage. There is existing flexible infrastructure at the Crimson 13-27 facility with optionality to East Crimson.

At East Crimson there was Q2 2020 average production of 3,609 boe/d. It is the continued eastward extension of the successful Crimson Lake development program. The Company’s West Pembina had Q2 2020 average production of 4,290 boe/d. It is in the proven oil rich Cardium trend with undeveloped primary development acreage. There is significant offsetting production from established Cardium players throughout the West side of Pembina, and also underdeveloped core acreage.

Central Pembina had Q2 2020 average production of 4,679 boe/d. The Company’s AB Viking had Q2 2020 average production of 880 boe/d. Concerning Obsidian’s Peace River Oil Partnership (PROP), it had Q2 2020 average production of 2,132 boe/d, with more than 3,064 boe/d shut-in during the quarter in response to low commodity prices. Nonetheless, 85 percent of earlier shut-in production has been returned to production as of July 1, 2020.

At the beginning of October, Obsidian Energy provided an update on its Alberta Site Rehabilitation Program (ASRP) grant applications. In partnership with its service providers, Obsidian received ASRP grants to date totaling $17 million and an additional $4 million in allocation eligibility as an Area Based Closure participant.

These awards will allow it to expand its abandonment activities for wells, pipelines, facilities, and related site reclamation starting in Q4 of 2020 and therefore lessen its decommissioning liability. Obsidian Energy said it will continue to be actively engaged with the Government of Alberta on further ASRP developments, and other Provincial and Federal programs, as they are announced.

Obsidian Energy Ltd. (OBELF), closed Tuesday's trading session at $0.336, up 1.8182%, on 15,427 volume with 22 trades. The average volume for the last 3 months is 139,336 and the stock's 52-week low/high is $0.129999995/$0.949999988.

Sigyn Therapeutics, Inc. (SIGY)

Zacks, Stocktwits, TradingView, Stockopedia, GuruFocus, Nasdaq, Fintel, Seeking Alpha, TipRanks, FX Empire, InvestorsHub, OTC Markets, Simply Wall St, Morningstar, Financhill, Business Insider, Investor Ideas, Stockhouse and MarketWatch reported earlier on Sigyn Therapeutics, Inc. (SIGY), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Sigyn Therapeutics, Inc. is a medical technology company centered on the treatment of life-threatening inflammatory conditions. A development-stage therapeutic technology enterprise, its focus is directed toward the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome (CSS) and not addressed with an approved therapy.

Sigyn Therapeutics has its corporate headquarters in San Diego, California. Co-Founders, Mr. Jim Joyce and Mr. Craig Roberts have 50-plus years of combined experience in the medical technology field. Moreover, Mr. Joyce has 20 years of public company Chief Executive Officer and Corporate Board leadership experience.

On October 19, 2020, Sigyn Therapeutics announced the completion of its earlier disclosed merger with Reign Resources Corporation (OTC: RGNP). The new combined company is now operating under the name Sigyn Therapeutics, Inc. (Sigyn). It started trading on October 20, 2020 under the ticker symbol SIGY.

Mr. Joyce, Chairman and Chief Executive Officer of Sigyn Therapeutics, stated, “The completion of this merger fulfills our objective to establish Sigyn Therapeutics as a publicly-traded company. To further the advancement of Sigyn Therapy, we are initiating a series of studies to reinforce the capability of our technology and to support our regulatory milestone objective to submit an Investigation Device Exemption (IDE) to The United States Food and Drug Administration (FDA) in 2021.”

Sigyn Therapy™ is a novel blood purification technology. The design of it is to mitigate Cytokine Storm Syndrome via the broad-spectrum depletion of inflammatory targets from the bloodstream. Cytokine Storm Syndrome is the hallmark of sepsis, which is the most common cause of in-hospital deaths. It claims more lives each year than all types of cancer combined.

Virus Induced Cytokine Storm (VICS) is associated with high mortality. It is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic opportunities include, but are not limited to, Bacteria Induced Cytokine Storm (BICS), Acute Respiratory Distress Syndrome (ARDS), and acute forms of liver failure, including Hepatic Encephalopathy.

Additionally, Sigyn Therapeutics believes there is an opportunity for Sigyn Therapy to stabilize or extend the life of patients waiting for the identification of a matched liver for transplantation. In such a situation, Sigyn Therapy would serve as a bridge to liver transplant.

Sigyn Therapeutics, Inc. (SIGY), closed Tuesday's trading session at $1.85, up 15.625%, on 625 volume with 4 trades. The stock's 52-week low/high is $0.109999999/$2.97000002.

Troubadour Resources, Inc. (TROUF)

Resource Maven, Junior Mining Network, MineStat, Northern Miner, Stockhouse, Smarter Analyst, Stockwatch, MarketWatch, StocksCafe, OTC Markets, Morningstar, Seeking Alpha, Market Screener, Investor Ideas, TMXmoney, Ask Finny, TipRanks, GuruFocus, Barchart, CEO.ca, FX Empire, Macroaxis, Mining.com, Wallet Investor, Proactive Investors, and Dividend Investor reported previously on Troubadour Resources, Inc. (TROUF), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Troubadour Resources, Inc. engages in the acquisition, exploration, and evaluation of mineral properties in Canada. Its concentration is on copper in the Province of British Columbia. An experienced team of professionals with proven records of accomplishment as mine finders manage Troubadour Resources. The Company formerly went by the name Grandore Resources, Inc. It changed its corporate name to Troubadour Resources, Inc. in February of 2017. Incorporated in 2012, Troubadour Resources is based in Vancouver, British Columbia.

Troubadour has its Amarillo Copper Project. The Amarillo Property consists of 9 mineral claims covering 5,449 hectares. The Amarillo Project is located 10km to the south of the past producing Brenda Mine, and proximal to Highland Valley, Craigmont, and Copper Mountain mines. It is positioned in the core of a major mining district.

The Amarillo Copper Property is strategically situated close to major low cost copper producers. This gives it a distinct advantage for future development potential. The three targets are the Trench Anomaly, the Copper Rich Skarn Deposit, and the North Copper Anomaly.

The multi-element signature of the Amarillo Project area is consistent with a large multiphase mineralizing system. It is acutely similar to some of the neighbouring world-class mining operations. Previously completed drilling encountered mineralization and alteration indicative of an alkalic porphyry system.

Three holes from the 2019 drill program followed up on the 2018 results. All holes encountered extensive lengths of highly anomalous copper, zinc, molybdenum, silver, and gold. In addition, 80 percent of drill meters have tested the highly prospective Trench Anomaly.

Earlier this month, Troubadour Resources announced that it entered into an option agreement with 1218802 B.C. LTD. , an arm's length vendor, to acquire a 100 percent interest in the 1,766 ha Texas property situated in the Greenwood Mining District in Southern British Columbia. It is positioned within the prolific Beaverdell mining camp that was a center of activity in the area from the late 1890s to the early 1900s.

Two recent grab samples from the Doorn vein assayed 241.96 g/t Au and 78.84 g/t Au, 319 g/t Ag and 8% Cu. Drill permitting is taking place. The property encompasses ground prospective for vein hosted precious metal deposits, based on a minimum of seven historical and newly discovered gold occurrences on the property and geological comparisons with the nearby Beaverdell Mine.

Last week, Troubadour Resources announced that it acquired by staking an additional 420 hectares (ha) of highly prospective ground contiguous to its Texas property situated in the Greenwood Mining District. The Texas property now encompasses an area of 2,186 ha. Troubadour Resources is mobilizing a field crew to site for a Phase I work program.

Troubadour Resources, Inc. (TROUF), closed Tuesday's trading session at $0.0682, even for the day, on 10,000 volume. The average volume for the last 3 months is 8,625 and the stock's 52-week low/high is $0.017249999/$0.079999998.

Lift & Co. Corp. (LFCOF)

OTC Markets, Stock Day Media, Technical420, Morningstar, Nasdaq, InvestorsHub, Investor Ideas, Stockwatch, TipRanks, Newsfilecorp, Market Screener, TradingView, Investing.com, Barchart, Stockhouse, Seeking Alpha and GlobeNewswire reported beforehand on Lift & Co. Corp. (LFCOF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Lift & Co. Corp. is a technology enterprise modernizing the cannabis industry. It is vertically integrated across the cannabis value chain with a differentiated and succeeding strategy. The Company monetizes a platform of advertising solutions, events, and data insights to cannabis businesses and consumers for making better-informed decisions. Lift & Co. has its corporate headquarters in Toronto, Ontario.

Lift & Co. monetized greater than 80 percent of selling licensed producers (LPs) in the last 12 months. The Company has realized 248 percent growth in annual trailing twelve month (ttm) revenues as of December 2018. Lift & Co. Tradeshows host 20,000-plus attendees and were the first platform channel. Moreover, the Company provides non-restricted product and brand information by way of product reviews. This creates an opportunity for B2C (Business to Consumer) marketing.

Lift & Co. looks to aggregate and connect the three most valuable stakeholders in the value chain. These are Consumers, Licensed Producers (LPs), as well as Licensed Retailers. Lift & Co. is an ecosystem of cannabis marketing and analytics platforms. These create unique competitive advantages for brands and retailers to capture consumers, budtenders and data insights.

Recently, Indiva Limited (NDVA.V) (NDVAF) and Lift & Co. announced the release of Indiva’s CannSell branded education module. The CannSell certification program, created by Lift & Co., in exclusive partnership with MADD Canada, is presently used in eight Canadian jurisdictions.

In addition, CannSell serves as the provincially-mandated training program for all cannabis retail workers in the Province of Ontario. These frontline staff members are responsible for educating consumers on the safe use of cannabis where it is sold. The Indiva education experience on the CannSell platform offers an overview of the Company, its product portfolio, as well as its dedication to quality, innovation and sustainability.

Lift & Co. also announced a strategic partnership with MCI USA, a recognized leader in meetings, events, and conferences, to grow Lift & Co.’s events portfolio. Also, the Company announced that in response to the present COVID-19 pandemic, it has successfully rescheduled its flagship Lift & Co. Expo in Toronto, Ontario to November 22-25, 2020 at the Metro Toronto Convention Centre (Toronto Expo 2020).

MCI USA is part of MCI Group, a global leader in event management. Lift & Co. chose MCI USA as a strategic growth partner based on the company’s record of scaling event portfolios and their prior investment in the North America cannabis industry via a strategic event partnership with the National Cannabis Industry Association (NCIA).

Lift & Co. Corp. (LFCOF), closed Tuesday's trading session at $0.0069, even for the day, on 1,100 volume. The average volume for the last 3 months is 37,168 and the stock's 52-week low/high is $0.0015/$0.115900002.

NutraLife BioSciences, Inc. (NLBS)

Zacks, TipRanks, Financial Insiders, Financial Buzz, Investors Observer, New Media Wire, EIN Presswire, Stockopedia, OTC.Watch, Super Stock Screener, GlobeNewswire, TradingView, Morningstar, last10k, Simply Wall St, Seeking Alpha, Investors Hangout, MarketWatch, InvestorsHub, Market Screener, TMXmoney, Whale Wisdom, and Wallet Investor reported earlier on NutraLife BioSciences, Inc. (NLBS), and today we report on the Company, here at the QualityStocks Daily Newsletter.

NutraLife BioSciences, Inc. operates a multifaceted life sciences company. In 2010, it formed to manufacture and distribute private label and branded nutraceutical and wellness products. In 2017, the Company launched its hemp-based PCR products. The Company formerly went by the name NutraFuels, Inc. It changed its corporate name to NutraLife BioSciences, Inc. in March of 2019. NutraLife BioSciences is based in Coconut Creek, Florida and the Company lists on the OTC Markets.

NutraLife BioSciences was founded by Mr. Edgar Ward, its Chief Executive Officer, President and Director, to engage in the development, manufacturing and distribution of unique and effective nutritional products. Since then, the Company has developed into a successful developer, manufacturer and distributor of more than 50 nutraceutical, wellness, and CBD (cannabidiol) products. NutraLife BioSciences’ brand portfolio consists of NutraHempCBD, PCR Pure, and HerbalShield.

Via its subsidiaries, Precision Analytic Testing, Inc., and PhytoChem Technologies, Inc., NutraLife BioSciences provides bulk material analytical, identity, potency and purity testing of raw hemp, hemp cultivation, raw bulk material extraction, and processing. Its dedication is to bringing high quality, effective, beneficial nutrients to the marketplace.

NutraLife Biosciences launched a new line of phytocannabinoid-rich (PCR) skincare and nutraceutical products in 2019 under its in-house brand PCR Pure. NutraLife's new skincare debuted with a facial gel cleanser, a daytime face cream, a nighttime face cream, and also an eye cream. The Company stated that all of the PCR Pure skincare products are formulated using effective, naturally derived ingredients that nourish and rejuvenate the skin, and contain different natural plant extracts, including the hemp plant. All of PCR Pure’s products are free of parabens, sulfates, sulfites and suitable for daily use.

Recently, NutraLife Biosciences announced that it is converting its existing nutraceutical bottling manufacturing operation to produce sanitizer products. The Company has increased its scope of production in accordance with 21 CFR 211–Current Good Manufacturing Practices for Finished Pharmaceuticals. Additionally, it has been assigned its labeler code from the Food and Drug Administration (FDA) so as to operate as an Over-the-Counter (OTC) manufacturer. NutraLife BioSciences is taking all required steps to build up production while adhering to FDA guidelines for the production, packaging, labeling, and distribution of the sanitizer products.

NutraLife BioSciences, Inc. (NLBS), closed Tuesday's trading session at $0.11, up 57.1429%, on 280,207 volume with 61 trades. The average volume for the last 3 months is 29,909 and the stock's 52-week low/high is $0.0071/$0.149900004.

StrikeForce Technologies, Inc. (SFOR)

The OTC Reporter, Capital Cube, Stockhouse, Silicon Investors, Insider Financial, Simply Wall St, Investing, Stockopedia, Tip Ranks, OTC Markets, MarketWatch, Penny Stock Tweets, Barchart, YCharts, GuruFocus, Morningstar, Investors Hangout, InvestorsHub, Street Insider, and Nasdaq.com reported earlier on StrikeForce Technologies, Inc. (SFOR), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

StrikeForce Technologies, Inc. provides strong two-factor, “Out-of-Band” authentication, and keystroke encryption along with mobile solutions. The Company helps to prevent Cyber theft and data security breaches for consumers, corporations, and government agencies. OTCQB-listed, StrikeForce Technologies is headquartered in Edison, New Jersey. BlockSafe Technologies is a subsidiary company of StrikeForce Technologies.

StrikeForce’s three chief products are ProtectID® (authentication), MobileTrust® (mobile device application), and GuardedID® (keystroke encryption). ProtectID® has an array of potential authentications methods. These methods include Out-of-Band Phone; Out-of-Band Push; Hard Tokens; Mobile Tokens; as well as Desktop Tokens.

GuardedID® stops malicious keylogging programs. It does so through encrypting keystroke data and routing it directly to one’s internet browser or desktop via a secure pathway that is invisible to keyloggers. MobileTrust® eliminates the threat from keylogging hackers. It does so through preventing them from detecting ones’ keystrokes.

StrikeForce provides the above-mentioned “Out-of-Band Authentication” and “Endpoint Protection” utilizing keystroke encryption, for signing on securely to one’s bank, broker, retail stores, and more. Also, the Company provides mobile device security on one’s Apple or Android devices.

The Company’s BlockSafe Technologies subsidiary centers on providing security solutions to protect blockchain and cryptocurrencies. BlockSafe Technologies will offer three innovatively redesigned security solutions. The first is Blockchain Defender™. The Company states that this will be the industry’s most completely dedicated Blockchain firewall. The other two solutions are Desktop Defender™ and Mobile Defender™. These two products will protect digital wallets and cryptocurrencies on MS Windows, Apple, iOS, and also Android platforms.

Recently, StrikeForce Technologies and Caroni Solutions, LLC announced the official Ecuadorian and South American product launch of StrikeForce Technologies ProtectID®.

Andrés Merino, South America spokesperson for Caroni Solutions, said, "We're excited to partner with industry leader StrikeForce Technologies to deliver the industry's most versatile, flexible and cost-effective multi-factor Out-of-Band authentication platform. ProtectID® is an affordable, flexible, and redundant authentication technology that Ecuador's banks, corporations, universities, and government agencies need to protect their networks and customers."

StrikeForce Technologies, Inc. (SFOR), closed Tuesday's trading session at $0.0129, up 253.4247%, on 329,335,436 volume with 5,250 trades. The average volume for the last 3 months is 5,778,899 and the stock's 52-week low/high is $0.003/$5.00.

InterCloud Systems, Inc. (ICLD)

RedChip, PennyStockProphet, Penny Pick Finders, INO.com Market Report, BUYINS.NET, GreatStockPix, Broad Street, StocksImpossible, Wealthpire Inc.,  Street Insider, PennyPro, OTCBB Journal, Promotion Stock Secrets, Stock Onion, Stock Tips Network, Buzz Stocks, Greenbackers, Jason Bond, Hit and Run Candle Sticks, Microcapmillionaires, Marketbeat, Planet Penny Stocks, and Investing Futures reported on InterCloud Systems, Inc. (ICLD), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

InterCloud Systems, Inc. is a top provider of cloud networking orchestration and automation solutions and services. The Company provides contemporary Information Technology (IT) and network solutions to the enterprise markets through cloud computing and professional services. InterCloud provides cloud services (SaaS, PaaS, and IaaS), professional consulting, data solutions, as well as maintenance services. InterCloud Systems is based in Shrewsbury, New Jersey. The Company has its Netlayer.io software platform.

InterCloud Systems’ mission is to enable carriers to speed up the installment of Virtualized Network and IT Services. InterCloud is a foremost provider of cloud networking orchestration and automation for Software Defined Networking (SDN) and Network Function Virtualization (NFV) cloud environments. The Company is a provider to the telecommunications service provider (carrier) and corporate enterprise markets.

InterCloud’s cloud solutions provide enterprise and service-provider customers the opportunity to adopt an operational expense model through outsourcing cloud deployment and management to the Company. InterCloud’s products and solutions include NFVGrid – NFVO Management & Analytics Platform. This is a full-scale next generation networking platform for virtualized network functions. NFVGrid is proprietary IP.  However, NFVGrid completely embraces Open Source.

Regarding its Professional Services, InterCloud Systems has a 24×7 practice for manifold technologies. These include Unix/Linux System Administration; Microsoft System Administration; VMware Administration; and Open Stack/Cloud Stack. Furthermore, these include Juniper Design, Operate & Support; Cisco Design, Operate & Support; and Citrix Design, Operate & Support.

InterCloud’s solutions include Disaster Recovery. The Company’s cloud backup enables one to backup their critical business data to a remote and secure location for quick disaster recovery.

Recently, InterCloud Systems announced the signing of a Letter of Intent (LOI) to undertake a merger with WaveTech Global, Inc. WaveTech will become a wholly-owned subsidiary of InterCloud Systems. InterCloud will be renamed WaveTech Global, Inc.

WaveTech is a worldwide next generation energy management company. It specializes in asset lifecycle extension, data-analytics, intellectual property (IP) development, and implementation services. WaveTech’s wide-ranging set of products include power asset life extension, operational servicing and automation, lifetime cost reduction, and real-time heterogeneous power source switching.

InterCloud Systems, Inc. (ICLD), closed Tuesday's trading session at $0.0005, up 66.6667%, on 3,362,433 volume with 9 trades. The average volume for the last 3 months is 7,553,173 and the stock's 52-week low/high is $0.000099999/$0.001.

Union Bridge Holdings Limited (UGHL)

OTC Research, StreetInsider, Hot Copper, OTC Markets, Simply Wall St, TradingView, Business Insider, WalletInvestor, 4-Traders, Morningstar, InvestorsHub, MarketWatch, Stockhouse, GuruFocus, TheHotPennyStocks, CapitalCube, Penny Fix, Barchart, and YCharts reported on Union Bridge Holdings Limited (UGHL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Union Bridge Holdings Limited engages in senior-care projects. The Company formerly went by the name Costo, Inc. It changed its corporate name to Union Bridge Holdings Limited in June of 2016. Established in 2014, Union Bridge Holding has its headquarters in Hong Kong.

In April 2018, the Company announced that its subsidiary, Windsor Honour Limited (WHL), entered into a Binding Heads of Agreement to enter into a cooperative venture with the owner of a land parcel of approximately 4,250 sq. m. in Chae Chang Sub-district, Sankamphaeng District, Chiang Mai Province, Thailand, for building and operating a senior-care nursing home facility. The facility is proposed to have four blocks, each with eight floors, and house about 400 residents.

Total investment in the Project for development and construction is estimated to be roughly 200 million Thai Baht. The Project would lease the land for 90 years with automatic renewal each 30 years.

Additionally, Union Bridge Holdings earlier announced that its subsidiary, Phoenix Creation Global Limited, entered into a Letter of Intent (LOI) with Shenyang Shenhe Yixi Home Care Service Center (Shenyang Yixi) to enter into a joint venture (JV) to promote the development of the elderly care business in China. Phoenix Creation Global would own 65 percent and Shenyang Yixi would own 35 percent.

Shenyang Yixi operates 12 community elderly day-care centers (elderly day-care centers or activity centers) and a district home-care service center (a home-based elderly care center to provide service to the elderly at home), which are government-owned. Shenyang Yixi would be responsible for the operation of the JV's nursing care facility. Phoenix Creation Global would be responsible for providing or arranging the financial support for the construction and rental costs.

In September, Union Bridge Holdings announced that its subsidiary, Sino Silver (Qianhai) Holdings Limited, rented an office in Chaoyang District, Beijing in August 2018. It has started the registration process of a subsidiary in Beijing to execute the strategies for the development of elderly and community services in Beijing. The application name of the subsidiary is Beijing Yihua Elderly Services Limited. Sino Silver was created to engage in the business of elderly home care services, senior care centers, as well as community services.

Mr. Joseph Ho, Union Bridge Holdings’ Chief Executive Officer, said, "The registration of a subsidiary in Beijing, the Capital of the PRC, demonstrates our determination to develop the elderly and community services in China. We strongly believe there is a huge market potential of the elderly and community services in China".

Union Bridge Holdings Limited (UGHL), closed Tuesday's trading session at $0.20, even for the day, on 10,100 volume. The average volume for the last 3 months is 429 and the stock's 52-week low/high is $0.075000002/$0.598999977.

Bravo Multinational,  Inc.  (BRVO)

RedChip, InvestorsHub, and MarketWatch reported on Bravo Multinational,  Inc. (BRVO), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

Bravo Multinational,  Inc. is a diversified Company listed on the OTC Markets Group’s OTCQB. Its primary focus is the development and expansion of the Casino Gaming Equipment holdings and business-related activities in Central and South America (specifically Nicaragua, El Salvador, and San Andres, Columbia). The Company’s multi-divisional growth strategy is driven via mergers, acquisitions, as well as new ventures. 

The Company previously went by the name Goldland Holdings Co. It changed its corporate name to Bravo Multinational, Inc. in April 2016. Bravo Multinational has its head office in Niagara-on-the-Lake, Ontario. 

At present, Bravo Multinational has divisions in Mining Properties and Casino Equipment. The Company, as it develops, will be adding divisions in International Business Consulting, Wholesale and Manufacturing, and Real Estate Acquisitions. In addition, Bravo holds gold/silver mining properties and claims in North America.

Pertaining to Mining Assets, this involves War Eagle Mines, Silver City, Idaho. Bravo executed a lease agreement with Silver Falcon Mining. This agreement provides for a yearly lease payment of $1,000,000 payable in monthly installments of $83,333 per month, and a royalty equal to 15 percent of the proceeds of any ore mined from Bravo Multinational property on War Eagle Mountain.

The Company’s Mining Assets (Current Claims) include the Poorman Lode Claim – Ownership Interest (OI) 29.167 percent; the London Lode Claim – OI 29.167 percent; the North Empire Lodge Claim - OI 29.167 percent; and the Illinois Central Lode Claim - OI 29.167 percent.

Current Claims also include the South Poorman Lode Claim – OI 29.167 percent; the Jackson Lode Claim - 29.167 percent; and the Oso Lode Claim - 29.167 percent.

Concerning Casino Gaming,  Bravo completed an acquisition transaction on May 6, 2016 with Centro de Entretenimiento y Diversion Mombacho S.A., based in Managua, Nicaragua.  Bravo received its first income from this business venture on June 1, 2016. Additional income payments will be received on the first of each month. 

Regarding this transaction, the Company is purchasing, in total, 500 slot and video poker gaming machines. All machines have been fully nationalized and are to be operated under a long-term (year 2033) nationwide national license. 

On August 16, 2017, Bravo completed an asset purchase for 300 slot and video poker machines. This provided an immediate new revenue stream for the Company.

The value of the contract is $3,618,000. The Company expects a roughly 30 percent annual return on the assets in Latin America, based on historical income data in comparable locations.

Bravo Multinational announced in August of 2017 its current review of a potential new “Casino Gaming” operation venture. Moreover, the Company announced its review of diversified business opportunities in the legalized marijuana (MJ) sector in Canada.

The Company commenced a comprehensive review of a large pending commercial “Marijuana Grow” operation with related real estate holdings for a possible joint venture (JV) investment, in Central Ontario, Canada. The licensing process for this venture is currently pending Health Canada’s government approvals.

Bravo Multinational,  Inc. (BRVO), closed Tuesday's trading session at $0.1853, up 105.8889%, on 95,200 volume with 24 trades. The average volume for the last 3 months is 5,213 and the stock's 52-week low/high is $0.050999999/$0.449999988.

TurnKey Capital, Inc. (TKCI)

MarketWatch, InvestorsHub, and TradingView reported on TurnKey Capital, Inc. (TKCI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, TurnKey Capital, Inc. aligns with and builds value in private, public, and development-stage companies. It works to identify opportunities in high-growth sectors, with an initial concentration on the developing cannabis industry. The Company formerly went by the name Train Travel Holdings, Inc. It changed its corporate name to TurnKey Capital, Inc. in February 2016. TurnKey Capital is headquartered in Fort Lauderdale, Florida.

A business advisory enterprise, Turnkey Capital provides a wide array of services. These include equity and debt financing for growth, strategic operational and management resources, and financial advice, modeling, and long term corporate and shareholder support.

The Company engages companies that have missing elements within the financials and operations of their company. These missing elements restrict companies’ ability to expand.

Turnkey Capital establishes value for company shareholders through securing debt and equity positions in select companies. As a result, the Company builds a group of undervalued businesses, which it will work to increase in value. Therefore, this enables TurnKey Capital shareholders to benefit from enhanced value alongside client companies.

In January 2017, Turnkey Capital announced that it executed a Letter of Intent (LOI) with Brand Strategy Group International. This is to engage in brand license and management within an extensive range of categories.

TurnKey Capital has identified Brand Strategy Group, Inc. (BSGI) as its first potential licensing partner. Brand Strategy Group owns all intellectual property (IP), licenses, trademarks, and trade names associated with the men's fashion brand, Phillip Acker™.

Recently, Turnkey Capital announced that it signed a strategic alliance agreement with Seminole Indian Company. This agreement is to provide business formation, development, as well as financial infrastructure services to unique opportunities afforded by tribal sovereignty.

Leading the Seminole Indian Company team is former Seminole Tribal Chairman, Mr. James E. Billie. Mr. Billie is credited with kindling the $33 billion Indian gambling industry.

Important requirements of TurnKey Capital are capital structure and shareholder relations. In essence, the Company approaches venture-capital from a financial viewpoint.

TurnKey Capital, Inc. (TKCI), closed Tuesday's trading session at $3.95, up 74.7788%, on 400 volume with 4 trades. The average volume for the last 3 months is 441 and the stock's 52-week low/high is $0.202099993/$3.95000004.

The QualityStocks Company Corner

Knightscope, Inc.

The QualityStocks Daily Newsletter would like to spotlight Knightscope, Inc..

Knightscope, a developer of advanced physical security technologies utilizing fully autonomous robots focused on enhancing U.S. security operations, today announced the appointment of Mallorie Burak as the company’s executive vice president and chief financial officer. Burak brings to the company over 25 years of expertise across a broad spectrum of industries ranging from early stage start-ups to multi-national public corporations. Over the span of her career, she has negotiated and managed over $500 million of successful financing and M&A deals and has focused the last 13 years on turnarounds and special situations for both public and venture-backed companies. To view the full press release, visit https://ibn.fm/4jv4C

Knightscope, Inc., founded in 2013 and based in Mountain View, California, is a leader in the development of autonomous security capabilities and are on target to disrupt the $500 billion security industry. Knightscope’s technology uniquely combines self-driving technology, robotics and artificial intelligence.

Knightscope designs and builds Autonomous Security Robots (ASRs) that provide 24/7/365 security to the places you live, work, visit and study. The company’s client list covers public institutions and commercial business operations, including ten Fortune 1000 companies to date. These ASRs have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools and corporations. ASRs act as highly cost-effective complementary systems to traditional security and law enforcement officials, providing an additional advantage by continuing to offer uninterrupted patrolling capabilities across the country, despite the pandemic (note: robots are immune).

The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs. Their machine-embedded thermal scanning capability even aided in preventing the breakout of a major fire.

The company has achieved several milestones since its creation in 2013, including:

  • Establishing itself in a 15,000-square-foot facility located in Mountain View, California, in the heart of Silicon Valley, where Knightscope designs, engineers and builds its technology;
  • Operating for more than one million hours in the field and securing contracts across five time zones;
  • Navigating through the global pandemic without interruption by continuing to operate on a daily basis across the nation and supporting clients classified as essential services; and
  • Continuing its hiring processes despite the current societal and economic disruption.

Growth Capital

With more than 10,000 investors and over $40 million raised since inception, Knightscope is poised to be an industry leader in the future of public safety and security.

The company is presently in the process of raising up to $50 million in growth capital as it prepares for a potential public listing. Knightscope has reserved ticker symbol ‘KSCP’ with Nasdaq.

Investors can buy shares exclusively through the company’s managing broker-dealer, StartEngine (http://nnw.fm/l9GLX) until July 20, 2020. Concurrent with this live offering and contingent upon various factors, including raising a sufficient amount of funds and meeting applicable listing standards, the company intends to begin preparation of an S-1 format Form 1-A and Nasdaq Capital Market application in anticipation of a possible public listing of the stock at the conclusion of the Regulation A+ offering.

Company Mission — The Greater Good

Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of America the safest nation in the world while supporting millions of law enforcement and security professionals across the country.

Crime has a negative economic impact in excess of $1 trillion annually. As crime is reduced, positive impacts will likely be realized across several aspects of society, including housing, financial markets, insurance, municipal budgets, local business and safety in general.

Knightscope CEO William Santana Li was recently interviewed by Kevin O’Leary, more commonly known as Shark Tank’s Mr. Wonderful. When asked to explain how the benefits provided by the ASRs outrank a human doing the same job, Li said, “First, just the simple presence of a physical deterrent causes criminal behavior to change. Second, the machines are self-driving cars that patrol all around and recharge themselves. They also generate 90 terabytes of data per year. No human would ever be able to process that. The robots are intended to be eyes and ears for the humans, not a one to one replacement.”

The Knightscope solution to reduce crime combines the physical presence of ASRs, sometimes referred to as proprietary Autonomous Data Machines, with real-time onsite data collection and analysis. The ASRs are fitted with eye-level 360° cameras, thermal scanning, public address announcements and various other features that work in tandem with humans to provide law enforcement officers and security guards unprecedented situational awareness.

Those 90 terabytes of data are then formatted in a useable way, so law enforcement can leverage that information and execute their responsibilities more effectively.

Public Safety Innovation

The company’s recurring revenue business model is set up to mimic the recurring societal problem of crime, and it takes into consideration the fact that innovation in the security and public safety industry has been stagnant for decades. Because the traditional practices of the sector have remained unchanged for years, automation has potential to drive substantial cost savings — and significant improvement in capabilities.

Human security guards are one of both the largest expenses and the largest liabilities for companies. Knightscope’s robots are offered at an effective price of $4 to $11 per hour, compared with approximately $85 and $30 per hour for an armed off duty law enforcement officer and an unarmed security guard, respectively.

This innovation has the potential to drive considerable cost savings. Based on these estimates, manufacturing costs can be recovered as soon as the first year of operation.

Product Offerings

The company has four patents and a framework of unique intellectual property. Knightscope currently offers a K1 stationary machine, a K3 indoor machine and a K5 outdoor machine. A K7 multi-terrain four-wheel version is in development.

The ASRs autonomously patrol client sites without the need for remote control, providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The data is accessible through the Knightscope Security Operations Center (KSOC), an intuitive, browser-based interface that enables security professionals to review events generated by the ASRs providing effectively ‘mobile smart eyes and ears’.

The ASRs and all the related technologies were developed ground up by the Company and are Made in the USA.

Management Team

Chief Executive Officer William Santana Li is a veteran entrepreneur, a former executive at Ford Motor Company and the founder of GreenLeaf, a company that grew to be the world’s second-largest automotive recycler and is now part of LKQ Corporation (NASDAQ: LKQ).

Chief Client Officer Stacy Dean Stephens brings his experience as a former Dallas law enforcement officer, as well as his skills as a seasoned entrepreneur, to assist on the client acquisition side.

Chief Intelligence Officer Mercedes Soria is an award-winning technologist and former Deloitte software engineer.

Chief Design Officer Aaron Lehnhardt brings over two decades of two- and three-dimensional product and industrial design in modeling and VR to the table, on top of his experience as a senior designer at Ford Motor Company.


Recent News

chart

Rritual Mushrooms Inc.

The QualityStocks Daily Newsletter would like to spotlight Rritual Mushrooms Inc..

Rritual, a plant-based consumer wellness brand, is positioning to take advantage of opportunity in the functional food and mushroom market with the fall launch of its innovative suite of premium functional mushroom and adaptogenic elixirs. “The health and wellness benefits of mushrooms and plant-based therapies are backed by decades of scientific research,” Dr. Mike Hart, president of Rritual, who also oversaw the development of the new line of products, stated of the launch (https://ibn.fm/bW2n6). “Rritual’s new line of elixirs embraces that research and provides consumers with an easy way to get a daily dose of the powerful effects.” To view the full article, visit https://ibn.fm/yZVRe

Rritual Mushrooms Inc. is a private company founded in 2019, whose declared purpose is to help people meet the demands of modern life with style and ease by incorporating functional mushrooms, adaptogens and superfoods into their diets.

The company manufactures premium plant-based products such as small-batch elixir powders, and each product features mindfully selected medicinal mushrooms and adaptogenic herbs. Pursuing customers with various need-states, Rritual offers products that fit every lifestyle.

Suite of Premium Rritual(TM) Products

Rritual recently announced the launch of its suite of premium functional mushroom and adaptogenic elixirs. These elixirs were developed by a leading team of scientists, doctors and experts across the wellness industry, under the guidance of Rritual President Dr. Mike Hart.

The initial product line includes:

  • Chaga (immune booster) – Full of bioactive polysaccharides, Rritual’s Chaga blend combines the Chaga mushroom with Eleuthero root for optimal immune system benefits.
  • Lion’s Mane (brain booster) – Designed to support cognitive function and brain health, Lion’s Mane is paired with Rhodiola root. The elixir can also help the body manage stress.
  • Reishi (stress support) – Rich in polysaccharides, triterpenes, amino acids and fatty acids, the Reishi blend is infused with Ashwagandha root. This combination aims to help the body and mind fight anxiety, with long term effects that may improve quality of sleep for those with restless minds.

“The health and wellness benefits of mushrooms and plant-based therapies are backed by decades of scientific research. Rritual’s new line of elixirs embraces that research and provides consumers with an easy way to get a daily dose of the powerful effects,” Hart said in a news release.

Rritual CEO David Kerbel noted that the company is proud to bring together age-old mushroom consumption practices and data-backed research to create new formulas that meet the needs of modern consumers. “Whether to relieve stress, increase mental output or boost immunity, we want to be a trusted and effective component of a consumer’s daily health and wellness routine,” he added.

Rritual Timeline

According to its investor presentation, Rritual has already fulfilled most of the milestones it set for Q1 and Q2 2020 as part of its growth and development timeline. So far, the company has completed formulation R&D, product line development, test marketing, brand development, logistics partnerships and agreements, initial distributor partnerships, seed financing and the phase one launch of its product suite.

Rritual E-Commerce Rollout Strategy

The company’s strategy for e-commerce rollout success consists of direct-to-consumer (D2C) sales through the use of multiple online platforms and through team connections to facilitate rapid expansion within the market.

In the first stage, Rritual will use its own website and Amazon to facilitate its D2C initiative, followed by leveraging its team connections to sell products through planned specialty e-commerce channels such as Costco, CVS, Walmart, and Vitacost using preexisting relationships.

Brick-and-Mortar Rollout Strategy

Using partnerships already in place with The Jet Collective and leveraging the preexisting connections of its team for direct discussions with global retail brands, Rritual’s brick-and-mortar strategy features a two-stage rollout that targets 15 leading retailers.

In the first stage, Rritual aims to launch with four non-competing chains, while utilizing best practice agreements (320 Sprouts stores, 330 H-E-B stores, 240 Meijer stores and 1,600 Publix stores). In stage 2, distribution is expected to advance to additional retail establishments (100 Wegmans stores, 77 Fresh Thyme stores, 440 Whole Foods stores, 120 Shaw’s stores, 400 Stop & Shop stores, 300 Wakefern/Shoprite stores, 610 Vitamin Shoppe stores, 90 Bartell Drug stores, 40 Giant Eagle market district stores and 1,800 Target stores), while collaboration with Kroger will take place within two sub-markets (300 Ralphs stores and 120 Harris Teeter stores).

Market Growth Outlook

As it is yet in its early stages, the functional mushrooms market is rife with opportunities for growth. At this time, no dominant brand is in place, and there remains an absence of a premium brand to lead the category.

The entire functional food market is currently valued at more than $275 billion, with global shifts supporting wellness and a 7.9% CAGR forecast through 2025. Demand for functional mushrooms is also growing, with a forecast rise from $23 billion to $34 billion by 2024 as a result of growing popularity due to the superfood’s unique properties that have been shown to boost immunity, cognitive function and more. The worldwide functional mushroom market is projected to exceed $50 billion by 2025, with recent data indicating an increase in demand for key mushroom varieties of up to 800%.

Management Team

David Kerbel, CPC, is CEO of Rritual and has over 30 years of senior experience in retail, brokerage and CPG industries. From 2008 to 2011, Kerbel served as Senior Vice President of Sales for Celsius Holdings Inc., helping that company achieve a number of important milestones. During his tenure, Celsius grew its retail sales from $400,000 to a multimillion-dollar figure, developed nationwide representation with CROSSMARK Inc. and established distribution with industry giants such as 7-Eleven, Ralph’s, C&S, Costco, BJ’s Wholesale, CVS, Walgreens, Walmart, Rite Aid, Target, Duane Reade and Stop & Shop. In total, Celsius’ new distribution stemming from Kerbel’s direct efforts led to $36 million in incremental sales in 2010 alone. He also implemented new procedures that led to a 10 percent reduction in operating expenses. Kerbel brings tremendous experience to the Rritual team, as well as vital relationships with industry leaders such as Walmart, Costco, Kroger, Walgreens, CVS, 7-Eleven, Safeway, Publix, Sprouts and more.

Warren Spence is the COO and a Director of Rritual. He has over 25 years in the food and beverage industry. His roles within the industry have included senior positions with brands like Red Bull and Olivieri. His specialization is in supply chain and operations systems. He was appointed Head of Supply Chain for Nude Beverages in 2019.

Dr. Mike Hart, MD, is the President of Rritual. His work has been published in peer-review journals about therapies involving cannabis and ketamine. His outspoken stance on these subjects landed him an appearance on the Joe Rogan Experience Podcast in 2019. On-air, he discussed the use of psychedelic medicines as a treatment for mental health conditions, including PTSD.

Stacie Gillespie is CCO and Director of Formulations for Rritual. She has over 25 years of leadership in the branding and product strategies used by wellness companies. She has leveraged this expertise for companies such as Aura Cacia, MegaFood and Gaia Herbs. She is the creator of multiple award-winning consumer health products.

Sarton Molnar-Fenton is Vice President of Sales-USA for Rritual. She started her career with Vitamin Water, with other large companies under her belt, including Danone, as a District Manager. She worked with Nestle on its Tribe Hummus brand and played an integral part in relaunching the brand, gaining category share and establishing product development partnerships with companies like Trader Joe’s. She also played a key role in launching the Hydralyte brand in the United States.

Scott Naccarrato is the company’s Vice President of Sales-Canada. He is experienced in sales with a deep connection in retail. Recently, he worked with Nutiva, assisting in the pioneering of Organic MCT oil, healthy fats and the plant-based protein categories. He is data-oriented in his approach, which has resulted in over $100 million in sales and double-digit year-over-year growth for the brands of which he has been a part.

Investment Considerations

  • Rritual’s suite of premium functional mushroom and adaptogenic elixirs is designed to offer various health benefits, such as increased immunity, cognitive function, stress management and more.
  • The company’s products are expected to be available online through Rritual’s site and Amazon by fall 2020.
  • The Rritual team has extensive ties and influential relationships with leading retail businesses, providing a wide market for growth.
  • The functional mushroom industry has no clear and dominant leader, allowing Rritual to target this role with its premium products. Rritual is currently the only premium brand on the market.
  • The global functional mushroom market is expected to exceed $50 billion by 2025, putting Rritual in the position for success.
  • Functional mushroom demand is expected to rise from $23 billion to $34 billion by 2024.

Recent News

chart

Friendable Inc. (FDBL)

The QualityStocks Daily Newsletter would like to spotlight Friendable Inc. (FDBL).

Friendable (OTC: FDBL), a mobile technology and marketing company engaging users through its proprietary mobile and desktop applications, today unveiled a new promotion for all active artists on the Fan Pass platform, offering them a paid promotion prior to any Halloween performances they schedule and broadcast through Fan Pass. To view the full press release, visit http://ibn.fm/VPKbW. Also today, NetworkNewsWire released a report featuring the company which details various investment considerations and how the company is “One to Watch.”

Friendable Inc. (FDBL) is a mobile technology and marketing company focused on connecting and engaging users through its proprietary mobile and desktop applications. Launched July 24, 2020, the company’s flagship offering is designed to help artists engage with their fans around the world and earn revenue while doing so. The livestreaming platform supports artists at all levels, providing exclusive artist content ‘Channels’, LIVE event streaming, promotional support, fan subscriptions and custom merchandise designs, all of which serve as revenue streams for each artist.

With Fan Pass, artists can offer exclusive content channels to their fans, who can use their smartphones to gain access to their favorite artists, as well as an all-access pass to all artists on the platform. Additionally, the Fan Pass team will deploy social broadcasters to capture exclusive VIP experiences, interviews and behind-the-scenes content featuring their favorite artists – all available to fan subscribers on a free trial basis. Subscriptions are billed monthly at $3.99, or about the cost of downloading a couple of songs, and VIP experiences are available at a fraction of the cost of traditional face-to-face meetups.

Friendable Inc. was founded by Robert A. Rositano Jr. and Dean Rositano, two brothers with over 27 years of experience working together on technology-related ventures.

The Fan Pass Mobile & Desktop App

Friendable Inc. launched its Fan Pass platform as a solution for artists and their fans as the COVID-19 pandemic and the associated shutdown have continued to severely hamstring the entertainment industry as a whole. Through Fan Pass, the company aims to reach artists at all levels looking to alter their touring schedules to include ‘Virtual Touring’, new revenue sources and innovative fan engagement opportunities that are expected to become permanent fixtures of artists’ touring routines moving forward.

Fan Pass creates an ecosystem that embraces fans of all kinds, feeding diehard followers and developing lasting connections with more casual supporters. Through the app, qualified artists are provided with a custom designed, exclusive ’Fan Pass Channel’ where they can invite fans and social followers from anywhere around the world to join in chats and live events – allowing fans to experience all there is to see of an artist in one place. Artists earn revenue from monthly fan subscribers, merchandise sales, tickets sold for virtual streaming events and generally from all content views or impressions on their channels. All content views and sales of every kind are reported to each artist through their dashboards, including real-time payout and earnings information.

Fan Pass’ exclusive ‘All Access VIP’ option provides fans with access to content, such as:

  • Live performances or online concerts
  • Backstage meetups before, during or after events
  • Livestreams of studio sessions
  • Behind-the-scenes footage of music video and photo shoots
  • Special interviews and one-on-one videos
  • Streams highlighting the artists’ daily lives

The Fan Pass platform is extremely intuitive, bringing each artist through a streamlined onboarding process, including building out artist ‘Channels’, scheduling LIVE events and designing special edition merchandise to be offered solely through exclusive Fan Pass merchandise stores.

“With the global pandemic disrupting the entertainment industry in such a profound way, artists have had to look to digital distribution and live virtual performances in order to maintain any earning opportunities. Fan Pass and our team are determined to provide solutions and support to all artists, their fans and the industry in general. We are excited about the opportunity we have to shape the future of virtual entertainment, revenue generation and artist/fan engagement,” Robert A. Rositano Jr., CEO of Friendable Inc., stated in a news release.

Market Opportunity

Artists rely heavily on revenue streams that are not often seen by those without intimate industry knowledge. When it comes to traditional performances, the sale of VIP/backstage or meet & greet passes to boost revenue can often become the majority of the artist’s annual tour revenue. Data provided by one of the company’s original entertainment partners, The Kluger Agency (TKA), suggests that as much as 18-23% of artists’ annual tour revenue has historically been derived from these VIP experiences.

The World Economic Forum reports that, in 2020, the six-month-plus disappearance of live music concerts is estimated to have cost “the industry more than $10 billion in sponsorships,” and individual artists are feeling the loss the most. Fan Pass is helping to bridge this gap, providing more affordable virtual VIP experiences that can be offered simultaneously to fans around the world.

While it’s free for artists to join, Fan Pass leverages a monthly subscription model paid by fans to generate revenues. These revenues are shared with all channel artists. In exchange for its platform features, live streaming tools, bandwidth, processing and handling, Fan Pass earns platform fees on each separately ticketed event, as well as splits with each artist on subscriber fees and merchandise designed and sold on the platform.

The U.S. video streaming industry is expected to hit $7.08 billion in value in 2021, with an estimated 100 million internet users watching online video content every day, according to data from Livestream.com. The same report suggests that 45% of live video audiences would pay for exclusive, on-demand video from a favorite team, speaker or performer. Through Fan Pass, Friendable Inc. is uniquely positioned to capitalize on this opportunity.

Friendable App

The company’s second application, Friendable, is an all-inclusive platform where users can meet, chat and date. The app has exceeded 1.5 million total downloads, with over 900,000 historical registered users and more than 580,000 historical user profiles.

Friendable Inc.’s Next Phase of Growth

To facilitate its next phase of growth, Friendable Inc. is seeking an additional $1 million in equity investment, with a follow-on funding that meets or exceeds $5 million. The company intends to utilize its relationships to secure the lowest cost of capital available, as these funds will drive technology advancements, increase head count, fund marketing initiatives and secure additional celebrity talent aimed at bringing larger fan audiences to each released event. These initiatives will assist in building recurring monthly (fan) subscribers, effectively generating recurring monthly revenue for each artist, as well. The next phase of growth is expected to play a key role in accelerating the company’s download and conversion of data for subscription revenue and merchandise sales.

The company’s primary goal is to establish Fan Pass as a premier brand and mobile platform dedicated to connecting and engaging users around the world. In support of this goal, it has entered into a partnership with Brightcove targeting OTT platform expansion, including leaders such as iOS, Android, Apple TV, Android TV, Roku and WWW.

In the highly competitive video streaming market, Friendable Inc. has tapped into an unmet demand from today’s ever-present ‘omni-users’ for constant contact with celebrities and influencers. Via Fan Pass, the company offers investors an opportunity to gain a stake in an organization catering to this new breed of omni-users and their influencers.

The application’s potential is clearly illustrated by the interest it has generated in recent weeks. From September 4 to October 12, the Fan Pass platform added 246 new artists, accounting for a 410 percent increase in just six weeks.

“We are extremely encouraged by the ongoing swell of interest as the value of our Fan Pass platform continues to resonate in the artist community,” Friendable CEO Robert A. Rositano Jr. stated in a news release. “We believe the live streaming functionality, our full-circle offering and diverse revenue opportunities the platform offers will continue to drive exponential growth as management remains focused on building long-term shareholder value.”

Management Team

Robert A. Rositano Jr. is the co-founder and CEO of Friendable Inc. He oversees the daily management and operational duties of all areas of the business. He has over 20 years of experience as a serial entrepreneur, bringing in over $60 million in liquidity events for the companies he has created or managed. Before starting Friendable Inc. with his brother, Rositano was a founding member of the internet’s first IPO, Netcom Online Communications Inc. It was sold to ICG, then to EarthLink in 1995. He has been a co-founder of several successful ventures, including Simply Internet Inc., Nettaxi.com and America’s Biggest Inc., among others. He also authored one of the first web directories for MacMillan Publishers.

Dean Rositano is the co-founder and Chief Technology Officer of Friendable Inc. He handles the day-to-day operations and guides the technical direction of the company. He has over 15 years of executive management, financial management, high technology operations and internet architecture experience. Before co-founding Friendable Inc., Rositano co-founded several other companies, including Checkmate Mobile Inc. and Latitude Venture Partners LLC, among others.

Friendable Inc. (FDBL), closed Tuesday's trading session at $0.0193, off by 8.0952%, on 2,004,116 volume with 8 trades. The average volume for the last 3 months is 183,379 and the stock's 52-week low/high is $0.016799999/$0.92900002.

Recent News

AzurRx BioPharma Inc. (NASDAQ: AZRX)

The QualityStocks Daily Newsletter would like to spotlight AzurRx BioPharma Inc. (AZRX).

AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company, recently announced positive results from the first five patients in its Phase 2 combination therapy trial of MS1819 for the treatment of severe exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis (“CF”). In the primary efficacy analysis, patients receiving MS1819 in combination with PERT therapy achieved a clinically meaningful improvement in the coefficient of fat absorption (“CFA”) at each of the three dose levels. To view the full press release, visit http://ibn.fm/G4kBU

AzurRx BioPharma Inc. (AZRX) is a clinical-stage biopharmaceutical company focused on developing treatments for gastrointestinal diseases using recombinant proteins.

The company’s lead drug candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients suffering from cystic fibrosis and chronic pancreatitis.

AzurRx has already completed two Phase 2 clinical trials for MS1819 and is currently pursuing approval through parallel monotherapy and combination therapy pathways.

The company was founded in 2014 and is headquartered in New York City, with scientific operations in Langlade, France, and clinical operations in Hayward, California.

MS1819 Clinical Trials

The two current ongoing clinical trials for MS1819 in cystic fibrosis (CF) are the Phase 2b Option 2 monotherapy trial and the Phase 2 combination therapy trial, using MS1819 together with porcine pancreatic enzyme replacement therapy (PERT), the current standard of care. Pending the Phase 2b trial outcome, the company intends to initiate a Phase 3 trial in cystic fibrosis.

  • Phase 2b CF Option 2 Trial – The study was initiated in Q3 2020, using MS1819 doses in enteric capsule form (2240mg and 4480mg). Topline data for the trial is anticipated in Q1 2021.
  • Phase 2 CF Combination Trial – The study was initiated in Q4 2019, using daily dose levels of PERT in combination with MS1819 dosages (700mg, 1120mg and 2240mg). Topline data is anticipated in Q2 2021.

These trials are currently addressing the treatment of EPI in patients with cystic fibrosis and chronic pancreatitis – an established global market with an estimated value in excess of $2 billion that has been growing at a CAGR greater than 20% over the past five years.

Results from AzurRx’s Phase 2b Option 2 trial of MS1819 in cystic fibrosis patients demonstrate that the non-porcine MS1819 lipase is well-tolerated by patients, with no significant safety signals observed at the 2240mg daily dose level.

“[W]e have evaluated four different enteric capsules and identified the best suitable formulation for MS1819 that provides gastroprotection of enzyme content and delayed release into the duodenum,” James Sapirstein, President & CEO of AzurRx, stated in a September 2020 news release (https://ibn.fm/27t4W). “Our clinical program continues to advance, and we are determined to develop MS1819 as a safer alternative to porcine pancreatic enzyme replacement therapy, significantly reducing the pill burden of cystic fibrosis patients.”

Financial Highlights

As of July 2020, AzurRx had raised gross cash capital of $22.1 million, including $15.2 million from Series B convertible preferred stock and warrants in July 2020 and $6.9 million from convertible promissory notes and warrants in December 2019 and January 2020. Notably, AzurRx solidified its financial position and created an effectively debt-free balance sheet by exchanging substantially all of its outstanding convertible notes into the Series B convertible preferred stock financing.

The company secured an additional $2.5 million in French Research Tax Credits, received in 2020, for the years 2017-2019 (https://ibn.fm/Qxk7O).

In a letter to shareholder, Sapirstein noted that ensuring the company maintains sufficient capital to support its business operations has been a key focus. He further stated that the company is in “a financially secure position” to complete its two Phase 2 MS1819 clinical trial programs and to begin preparations in 2021 for a pivotal Phase 3 study.

The company has no current plans to access additional financing, as it believes it has enough cash to fund existing operational and clinical objectives through Q3 2021.

Management Team

James Sapirstein is the President and CEO of AzurRx BioPharma. He was previously the CEO and a board member for ContraVir Pharmaceuticals Inc., which is now known as Hepion Pharmaceuticals Inc. (NASDAQ: HEPA). Mr. Sapirstein has almost 36 years of experience in the pharmaceutical industry, with expertise in drug development and commercialization. He currently serves on the Emerging Companies and Health Section boards of the BIO (Biotechnology Innovation Organization) and is Chairman Emeritus of BioNJ. He earned his Bachelor’s degree in Pharmacy from Rutgers University and has an MBA in management from Fairleigh Dickinson University.

Daniel Schneiderman is the Chief Financial Officer of AzurRx. He previously served as the CFO of Biophytis SA and its U.S. subsidiary, Biophytis, Inc., clinical-stage biotechnology companies focused on the development of pharmaceutical candidates for age-related diseases. He was appointed to the AzurRx position in January 2020, bringing to the team over 18 years of experience in capital markets and finance operations. Mr. Schneiderman holds a degree in economics from Tulane University.

James Pennington, M.D., is the Chief Medical Officer of AzurRx. Before joining the team, he was the Chief Medical Officer and Senior Clinical Fellow for 11 years at Anthera Pharmaceuticals. Before becoming a part of the biotech industry, Dr. Pennington was on the Medical Faculty of Harvard Medical School for 10 years. He received his medical degree from Oregon Health & Science University.

Martin Krusin is the Senior Vice President for Corporate Development at AzurRx. He has 20 years of experience in business development, strategic marketing, financing and operations in the health care, financial services and consulting sectors. Before joining AzurRx, he was the VP for Business Development at FluoroPharma Medical Inc. Mr. Krusin received his MBA from Columbia Business School in finance and marketing, an MPhil. in political economy from Oxford University and a BA in international relations from Swarthmore College.

Dinesh Srinivasan, Ph.D., is the Vice President for Translational Research at AzurRx. He has over 15 years of experience leading drug discovery and development in the pharmaceutical industry. He began his career as a post-doctorate fellow at Roche Palo Alto. Dr. Srinivasan received his MSc in Biotechnology from the University of Mumbai, India, and a Ph.D. in Pharmacology and Toxicology from the University of Arizona – Tucson.

Ted Stover is the Product Development Director at AzurRx. He joined the company in 2020 to oversee CMC and Project Management. Before joining AzurRx, he spent 20 years focused on manufacturing operations and analytical method development for all stages of pharmaceutical drug development. Mr. Stover earned his MBA from the University of Florida.

AzurRx BioPharma Inc. (AZRX), closed Tuesday's trading session at $0.7899, up 1.2562%, on 61,237 volume with 178 trades. The average volume for the last 3 months is 354,389 and the stock's 52-week low/high is $0.370867997/$1.93830001.

Recent News

VistaGen Therapeutics Inc. (NASDAQ: VTGN)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics Inc. (NASDAQ: VTGN).

InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Stock2Me Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The Stock2Me Podcast features a fascinating array of companies and individuals, many of whom are actively revolutionizing age-old business practices within their respective markets. Stock2Me’s latest podcast features Shawn Singh, CEO of VistaGen Therapeutics Inc. (NASDAQ: VTGN) .

VistaGen Therapeutics Inc. (NASDAQ: VTGN) is a biopharmaceutical company committed to developing and commercializing a new generation of medications that go beyond the standard of care for anxiety, depression and other central nervous system (CNS) disorders.

The company is headquartered in South San Francisco, California, the “Birthplace of Biotechnology,” among the largest cluster of biotechnology companies in the world.

New Generation Medications

VistaGen currently has three innovative CNS drug candidates in its pipeline: PH94B, PH10 and AV-101. With a differentiated mechanism of action and an exceptional safety profile in all clinical studies to date, each of VistaGen’s three drug candidates offers significant commercialization potential in multiple large CNS markets.

PH94B

Fast-acting (10-15 minutes), non-systemic and non-sedating in Phase 2 clinical studies, PH94B is a first-in-class neuroactive nasal spray that, administered in microgram doses, binds to chemosensory receptors in the nasal passage that trigger neural circuits responsible for suppressing fear and anxiety caused by stressful social or performance situations.

PH94B is currently being developed as an acute treatment of anxiety in adults with Social Anxiety Disorder (SAD). In December 2019, PH94B became the first drug candidate to be granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for development of a treatment for SAD, positioning it to potentially become the first FDA-approved fast-acting acute treatment for adults with the anxiety disorder, if planned Phase 3 studies are successful.

A successful Phase 2 program has been completed, and, after achieving consensus with the FDA in mid-2020 that the design of its Phase 3 studies of PH94B in SAD may mirror the design of the highly statistically significant (p=0.002) Phase 2 public speaking study of PH94B in SAD, the company’s preparations for pivotal Phase 3 clinical development of PH94B are underway.

To support Phase 3 development and commercialization of PH94B for anxiety disorders in large anxiety disorder markets in Asia, VistaGen recently entered into a strategic licensing and collaboration agreement with EverInsight Therapeutics, a company formed and currently funded by a large global venture capital firm, CBC Group. The company received a $5 million non-dilutive upfront license payment from EverInsight in August 2020. If Phase 3 development is successful, VistaGen is eligible to receive additional development and commercial milestone payments of up to $172 million, plus tiered royalties on sales of PH94B in Greater China, South Korea and Southeast Asia. VistaGen retains exclusive rights to develop and commercialize PH94B in all other markets.

VistaGen is also assessing potential Phase 2A clinical development opportunities to evaluate PH94B in a range of other anxiety disorders, including:

  • Adjustment Disorder with Anxiety
  • Generalized Anxiety Disorder
  • Postpartum Anxiety
  • Perioperative Anxiety
  • Panic Disorder
  • PTSD

PH10

PH10 is an investigational fast-acting synthetic neuroactive nasal spray with therapeutic potential in a wide range of neuropsychiatric indications involving depression and suicidal ideation. VistaGen is initially developing PH10 as a potential fast-acting, non-sedating, non-addictive new generation treatment of major depressive disorder (MDD).

Upon self-administration, a microgram-level dose of PH10 sprayed into the nose binds to nasal chemosensory receptors that, in turn, activate neural circuits in the brain that lead to rapid-onset antidepressant effects, without side effects, systemic exposure or safety concerns that may be caused by FDA-approved drug treatments for MDD, including oral antidepressants and intranasal esketamine.

In a published exploratory Phase 2A MDD study, PH10 demonstrated rapid-onset and sustained antidepressant effects without the serious psychological side effects and safety concerns of ketamine-based therapy.

Following successfully completed Phase 2A development of PH10 for MDD, the company is currently preparing for a Phase 2B program in MDD.

VistaGen is also assessing the potential for Phase 2A clinical development of PH10 in a range of other depression-related indications, including:

  • Postpartum Depression
  • Treatment-resistant Depression
  • Suicidal Ideation

AV-101

Part of a class of new generation investigational medicine in neurology and neuropsychiatry known as N-methyl-D-aspartate receptor (NMDAR) modulators, AV-101 is an oral prodrug of 7-chloro-kynurenic acid (7-Cl-KYNA), a potent and selective NMDAR glycine site antagonist. This drug candidate has the potential to serve as an innovative treatment for MDD and multiple neurological indications where current therapies are unsatisfactory.

VistaGen is currently evaluating AV-101, in combination with FDA-approved probenecid, in a range of neuropsychiatric and neurological indications, with both MDD and Neuropathic Pain already granted Fast Track designation by the FDA. The company is assessing the combination for a potential Phase 1B study to support a potential Phase 2A program in one or more of the following indications:

  • Major Depressive Disorder
  • Neuropathic Pain
  • Levodopa-induced dyskinesia associated with Parkinson’s disease therapy
  • Epilepsy
  • Suicidal Ideation

CNS Therapeutics Market Outlook

The global CNS therapeutics market is estimated to reach $130 billion by 2025. The market was valued at approximately $82.3 billion in 2017 and is anticipated to grow at a healthy CAGR of more than 5.93% from 2018 to 2025. Even before the onset of the anxiety- and depression-provoking stressors from the COVID-19 pandemic, this growth was expected to be driven by a rise in mental illnesses and increased awareness of psychiatric disorders (https://nnw.fm/K2m0s) – all likely to be amplified by the diverse impacts of the pandemic.

The two most common mental health conditions – anxiety and depression – cost the global economy an estimated $1 trillion each year. The impact of these conditions is particularly devastating among the young. Industry data suggest that approximately 20% of the world’s children and teens are affected by mental health conditions, and suicide is the leading cause of death among 15- to 29-year-olds (https://nnw.fm/oftNb).

VistaGen’s mission is to help address the unmet needs of patients suffering from CNS disorders whose current treatments are either inadequate or generate debilitating side effects and serious safety concerns, including risk of abuse and death.

“Now more than ever, the new generation anti-anxiety and antidepressant medications we are developing at VistaGen – PH94B, PH10 and AV-101 – are relevant, necessary and demand the highly-focused and passionate efforts of our team and partners, with the support of our stockholders, to advance them to patients whose lives are disrupted by anxiety and depression disorders,” VistaGen CEO and Director Shawn K. Singh said in his closing remarks at the company’s 2020 Annual Meeting of stockholders.

Management Team

Shawn K. Singh, J.D. is the Chief Executive Officer and a Director of VistaGen. He has served on the company’s board of directors since 2000. He has nearly 30 years of experience serving in numerous senior management roles across multiple industries, including private and public biotechnology, pharmaceuticals, medical devices, venture capital, contract research and development, and law. Singh has a B.A. with honors from the University of California – Berkley. He has a J.D. degree from the University of Maryland Carey School of Law. He is also a member of the State Bar of California.

H. Ralph Snodgrass, Ph.D., is the Founder, Chief Scientific Officer and Director of the company. Snodgrass has more than 20 years of experience in the biotechnology field as a senior manager. He is recognized as an expert in stem cell biology, with over 28 years of experience using stem cells as biological research tools to promote development and drug discovery. He received a Ph.D. in immunology from the University of Pennsylvania. Snodgrass has published over 50 scientific papers with more than 17 patents and a number of patent applications.

Mark A. Smith, M.D., Ph.D., is VistaGen’s Chief Medical Officer He has over 20 years of pharmaceutical industry experience, primarily with CNS drug development. Smith has been a successful leader in the discovery and development of approximately 20 investigational new drugs. He has been a part of numerous CNS-related clinical trials. Smith received a bachelor’s and Master of Science from Yale University and a Doctor of Medicine and Doctor of Philosophy in Physiology and Pharmacology from the University of California – San Diego. He completed his residency in the psychiatry department at Duke University Medical Center.

Jerrold D. Dotson, CPA, is the Vice President, Chief Financial Officer and Secretary of VistaGen. He has over 25 years of experience in senior management positions in finance and administration at both public and private companies. Dotson is a licensed CPA in California and received his B.S. degree (Cum Laude) in business administration with a concentration in accounting from Abilene Christian College.

Mark A. McPartland is the company’s Vice President of Corporate Development and Investor Relations. He has over 20 years of experience in senior management roles in corporate development and investor relations at both public and private companies. McPartland received his Bachelor’s in business administration and marketing from Coastal Carolina University.

VistaGen Therapeutics Inc. (NASDAQ: VTGN), closed Tuesday's trading session at $0.755, up 6.338%, on 405,531 volume with 972 trades. The average volume for the last 3 months is 1,788,512 and the stock's 52-week low/high is $0.294299989/$1.30999994.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) was featured today in a publication from BioMedWire, examining how, from the start of the pandemic, researchers and clinicians have been searching for nasopharyngeal swab alternatives. Tests administered using these swabs are hard to scale up for mass testing, they put health workers in closer contact with individuals who may be infected, and they require more supplies. Saliva has been suggested as an easy and low-cost alternative. However, its accuracy and efficacy remain a point of conflict.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Tuesday's trading session at $1.84, up 1.6575%, on 5.866 volume with 67 trades. The average volume for the last 3 months is 93,420 and the stock's 52-week low/high is $1.25820004/$5.68989992.

Recent News

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: ATUMF)

The QualityStocks Daily Newsletter would like to spotlight GoldHaven Resources Corp. (CSE: GOH) (OTCQB: ATUMF).

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: ATUMF) was featured today in a publication from MiningNewsWire, examining how, for the past two years, the Unites States has made an effort to decrease its dependence on foreign mineral imports while encouraging domestic miners to provide these minerals. The America First mining program designated 35 products that were important to the national and economic security of the country; China currently dominates the production of many of these important minerals, including aluminum. China is the world’s largest producer of aluminum with a yearly production capacity of roughly 36 million tons.

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: ATUMF) (formerly Altum Resources Corp.), a Canada-based company engaged in the business of acquiring and exploring mineral resource properties, recently announced its entry into agreements to acquire seven advanced gold projects in the Maricunga Gold Belt of Chile that hosts over 100 million ounces of gold within the last 10 years.

Chilean Gold Properties Being Acquired

On April 17, 2020, GoldHaven Resources entered into an agreement to purchase a 100% interest in two gold projects located in the Maricunga Gold Belt of Northern Chile. The first property, Rio Loa, is located 25 kilometers south of Gold Fields Ltd.’s Salares Norte, where, this year, a five-million-ounce discovery was made. The second property, Coya, is located only 10 kilometers east of the Kinross La Coipa open pit mine, which has produced over 7.5 million ounces of gold to date.

Rio Loa Project

Initial geophysical studies of the Rio Loa site have exposed highly anomalous ardennite and lead values, a key characteristic of gold mineralization within silicified resistive bodies. The studies have also produced initial findings which are similar to those seen at contiguous mines, such as Salares Norte (operated by Gold Fields), which has over five million ounces in estimated gold deposits.

The potential economics for the site look particularly promising when taking the unit costs at the neighboring Salares Norte mine into account. Gold Fields has estimated that its production AISC (all-in sustainable costs) will approximate $552 per ounce and have forecast a 2.3-year payback period for its initial investment, assuming a $1,300 per ounce gold price.

Coya Project

The Coya site is located within close proximity to one of the richest and largest epithermal gold and silver districts in Chile and is in close proximity to active mining sites, specifically the La Coipa mine owned by Kinross. A study carried out in 2017-2018 on the Coya site of 796 rock chip samples found favorable gold and silver values, in some cases ranking as high as 764 grams/tonne of gold and 719 grams/tonne of silver – values which are near certain indicators of potential gold and silver deposits. The La Coipa mine (Kinross) has produced over 6.9 million ounces of gold to date.

On August 11, 2020, GoldHaven Resources acquired five potential gold projects in the Maricunga Gold Belt of Northern Chile. The Maricunga hosts discoveries within the last 10 years of over 100 million ounces of gold and over 450 million ounces of silver. These newly acquired properties are in close proximity to seven other mines, which possess an estimated aggregate of 81 million ounces of gold in total reserves.

GoldHaven’s five new projects cover a total area of approximately 22,600 hectares, or 226 square kilometers, located in the northern portion of the Maricunga Belt in proximity to the 5 million-ounce gold equivalent Salares Norte project owned by Gold Fields. Gold Fields announced in April 2020 its intention to proceed with the development of Salares Norte at a cost of $860 million, with a $138 million expenditure budgeted for 2020.

The Maricunga Belt extends approximately 150 kilometers north-south and 30 kilometers east-west, straddling the border between Chile and Argentina. This region hosts known mineral resources of more than 100 million ounces of gold, 450 million ounces of silver and 1.3 billion pounds of copper.

The Maricunga project’s opportunity came about as a result of a $150 million initiative launched by the Chilean Economic Development Agency (“CORFO”), with the objective of encouraging exploration and mining prosperity in Chile and strengthening Chile’s position as a world leader in the sector.

As part of CORFO’s program, a total of $15.3 million was given to private equity fund IMT Exploration to evaluate 403 projects, beginning in 2011. This led to a generative program carried out from 2016 to 2019, resulting in 126 potential epithermal targets from which 57 field evaluations were made. Due diligence work followed on 19 of these. Work programs were then conducted, including geological mapping, rock and soil sampling and TerraSpec (PIMA) analyses on geochemical grids for alteration mapping, and, as a result, the five high-priority Maricunga projects were identified. No drilling has been carried out on any of the Maricunga projects.

Securing Financing for Upcoming Operations

In conjunction with its announcement regarding its acquisition of five Chilean mining interests, GoldHaven Resources also detailed plans for a non-brokered private placement of 11.5 million units at a price of $0.35 per unit, for gross proceeds of $4,025,000. Each unit will consist of one share of the company and one warrant, the latter of which can be exercised to acquire an additional share of the company for a period of 18 months from the date of issuance at a price of $0.50 per share. Net proceeds from the offering are intended to be used to fund general expenses, as well as exploration and drilling of its mineral properties.

Gold Prices Hit Record High in 2020

Gold prices have been on a remarkable run in 2020, breaking above $2,000 per ounce for the first time on record. Having begun the year at $1,515 per ounce, the precious metal has seen a huge surge on the back of widespread economic uncertainty stemming from governments’ worldwide propensity to expand the money supply, from the reduction of the value of the U.S. dollar as expressed by the decrease in the U.S. dollar index, and from the very real economic effects of the COVID-19 pandemic.

Global central banks have carried out 144 interest rate cuts thus far in 2020, reducing rates by a cumulative 5,035 basis points (http://nnw.fm/jzZt0). Meanwhile, the IMF has estimated that global governments have introduced fiscal support measures amounting to over $9 trillion since the start of the pandemic (http://nnw.fm/Or9rI). The resulting weakness in the U.S. dollar and eventual inflationary pressures stemming from these measures has prompted a number of investment banks to boost their near-term outlooks for gold prices, with Bank of America raising its 18-month gold price target to $3,000 per ounce (http://nnw.fm/PQJtc).

Leadership Team

David Smith, President, CEO and Director, has been immersed in the mining industry for the last eight years, working in corporate development and finance. Prior to GoldHaven Resources, Smith cofounded a multifaceted real estate development and sales company, which has now been in operation for over 35 years. He also cofounded two successful environment-focused companies listed on the Toronto Stock Exchange. Both companies were sold independently and returned a significant profit for shareholders.

Darryl Jones, Chief Financial Officer, is a finance executive and CPA with over 30 years of public company and project buildout experience. Most recently, Jones served as the CFO of Lupaka Gold Corp., retiring in June 2018. Prior to that, Jones serves as CFO of Corriente Resources, which was sold to CRCC-Tongguan in May 2010 for C$680 million.

Patrick Burns, VP Exploration and Director, is a Canadian geologist with over 40 years of experience throughout the Caribbean and Central and South America. He played a direct role in the discovery of the Escondida porphyry copper deposit in Chile and has been involved in publicly traded mining companies, predominantly in Chile, for 35 years.

Marla Ritchie, Corporate Secretary, brings over 25 years of experience in public markets to the GoldHaven team. Throughout this time, she has worked as an administrator and corporate secretary specializing in resource-based exploration companies. Currently, Ritchie is the corporate secretary for several companies, including International Tower Hill Mines Ltd. and Trevali Mining Corp.

Gordon Ellis, Director; has over 50 years’ experience in mining and resource development. A professional engineer and entrepreneur, he has held multiple senior management and director roles with public mining companies, as well as a multi-billion-dollar ETF fund. Ellis holds an MBA in international finance and a Chartered Directors designation.

Scott Dunbar, Director is a professor and head of multiple departments at the University of British Columbia, including mineral extraction and mining innovation, as well as mining engineering. He has been involved in projects around the world in regard to mining exploration, geotechnical engineering and mine design. Dunbar received his PhD in geophysics and civil engineering from Stanford University.

GoldHaven Resources Corp. (OTCQB: ATUMF), closed Tuesday's trading session at $0.2545, up 6.0417%, on 18,625 volume with 13 trades. The stock's 52-week low/high is $0.109999999/$0.446000009.

Recent News

Pac Roots Cannabis Corp. (CSE: PACR)

The QualityStocks Daily Newsletter would like to spotlight Pac Roots Cannabis Corp. (PACR).

Pac Roots Cannabis Corp. (CSE: PACR) was featured today in the 420 with CNW by CannabisNewsWire. An attempted robbery that took place on Tuesday, Oct. 20, in a medical cannabis dispensary in Detroit went south for the suspects. Instead of becoming victims, the dispensary workers put up a fight. Two workers opened fire inside the facility on the three armed suspects who were trying to rob the store. As a result, two of the three suspects received nonlife-threatening injuries and were arrested; they are now recovering at a local hospital under police custody. The third suspect escaped.

Pac Roots Cannabis Corp. (CSE: PACR) is a Canadian cannabis company dedicated to producing premium-quality strains and products by leveraging a genetics-focused approach.

The company began operations in 2012, with activities primarily directed toward exploration and development of mineral properties in Canada. Today, it is focused on cannabis and hemp cultivation, leveraging high-end genetics and specialized cultivars to produce top quality products. Pac Roots has announced multiple promising initiatives in recent months, including its formation of an outdoor premium hemp joint venture with partner Rock Creek Farms in British Columbia, Canada, and its agreement to acquire all issued and outstanding shares of a firm holding 250 acres of land in the famed Fraser Valley Region of British Columbia.

Pac Roots is also in the process of completing its 20,000 square foot cultivation facility in Lake Country, British Columbia. The facility is expected to feature approximately 7,600 square feet of cultivation space that will enable the company to cycle through an elite line of 350+ unique, high-grade cultivars. Pac Roots expects to receive a cultivation license for the facility in the fourth quarter of 2020.

High-End Selectively Bred Genetics

Pac Roots focuses on high-end genetics in order to maximize the quality of its products while maintaining high yields and profit margins.

Through the process of artificial selection, farmers and cultivators have been adapting their plants to develop particular phenotypic traits for generations. Historically, this practice was restricted to underground cannabis producers developing their own strains.

The legalization of the cannabis industry has given producers access to thousands of cultivars located throughout the world while accelerating research into cannabis genetics. By carefully selecting strains, growers can control the size, color, smell, density and texture of cannabis buds, thereby creating distinctive, premium cannabis products.

Plants are bred to thrive in specific growing environments. This maximizes the yield of high-quality, resilient cannabis. Medical cannabis strains can also be tailored for specific medicinal purposes.

A strategic partnership with Phenome One, a plant breeding management and analytics firm, gives Pac Roots access to some of the world’s best cannabis genetics from the largest genetic library in Canada. The company is using these genetics to develop unique strains featuring a variety of beneficial characteristics.

The company’s 350+ licensed live cultivars and over 1,800 seed varieties are the result of a meticulous gene selection process, through which as many as 600 individual plants may be grown to produce a single strain. Selecting optimized genetics in this way provides benefits beyond simply producing a high-end product. In addition to potency and bud quality, cannabis plants are bred for yield and resilience. By selecting genetics that result in larger and more numerous buds on each plant, Pac Roots is able to grow more cannabis per grow light.

Breeding plants to be more resilient also reduces the cost and labor required. These factors, combined with the premium price point associated with top-quality cannabis, have the potential to improve Pac Roots’ overall profit margin.

Partnership with Phenome One

Pac Roots has secured its cultivars through a strategic licensing agreement with Phenome One. Under the agreement, Pac Roots has unlimited access to Phenome One’s live genetic library, including any of Phenome One’s cultivars and its growing, breeding and cloning IP.

Phenome One is an agricultural technology company focused on providing software solutions to seed companies. Phenome One’s platform gives its partners access to a massive database of detailed information on over 350 unique cannabis cultivars to support each stage of the breeding process. Each cultivar has been laboratory analyzed and rigorously field-tested, with data going back more than 30 years.

Using Phenome One’s data, Pac Roots plans to grow a variety of cannabis plants optimized for certain traits. One such trait will be plants with an abundance of cannaflavin, a rare terpene with high anti-inflammatory properties. Phenome One’s library could enable Pac Roots to produce plants that are bred to thrive in a range of different growing climates, including plants suited to grow in cold weather and plants that are resilient to region-specific fungi.

Joint Venture with Rock Creek Farms of British Columbia

Pac Roots recently entered a definitive investment agreement with Rock Creek Farms, a reputable agricultural enterprise, for a 100-acre commercial hemp operation in Rock Creek, British Columbia. The growing space is located in the highly lucrative farming area known as the ‘Golden Mile’ in the South Okanagan Valley of British Columbia. (http://nnw.fm/Gbf9I).

Under the agreement, the two companies have formed an outdoor premium hemp joint venture company to which Pac Roots is providing an aggregate of $450,000 in capital and Rock Creek Farms is contributing two commercial leases for 100+ acres of growing space, along with cultivation licenses, agricultural infrastructure and equipment, consulting services, intellectual property relating to hemp operations and proprietary biomass storage methods. Pac Roots holds a 60 percent interest in the project.

About 127,500 premium hemp CBD seedlings were planted across 100 acres as of early July 2020. The joint venture is planting a premium grade CBD hemp variety utilizing the rich native soil and both traditional and custom farming techniques.

“Our operational partners at Rock Creek Farms bring decades of generational farming expertise in one of Canada’s pre-eminent growing regions,” Pac Roots President and CEO Patrick Elliott said in a news release detailing the venture. “It will be an exciting outdoor growing season for the joint venture as we anticipate a successful harvest in the fall.”

Infinite Development Possibilities at Fraser Valley Property in British Columbia

In mid-July 2020, the company initiated a share purchase agreement with 1088070 BC. LTD. (“1088”) and its shareholders for the acquisition of all issued and outstanding shares of 1088 (http://nnw.fm/xlpw7). Notably, 1088 owns and controls 250 acres of land spread over nine parcels in the Fraser Valley Regional District.

The Fraser Valley Regional District is one of the most productive and intensively farmed areas of Canada, offering access to high-quality soil, favorable climate, water and a local market of 2.5 million people. Agriculture in this region yields an annual economic value of more than $3 billion.

The closing date for the transaction is slated for September 4, 2020, after a 51-day due diligence period. According to Elliott, the addition of such a significant package of land is a major step for Pac Roots.

“This land has no zoning restrictions and is not situated within the agricultural land reserve, which provides for infinite development possibilities,” Elliott added in a July 2020 news release.

Board of Directors member Chad Clelland also welcomed the acquisition, adding that between Fraser Valley and Rock Creek – both of them among the most productive agricultural regions in Canada – Pac Roots is very well positioned for production and the future development of its hemp and cannabis infrastructure.

The RAD Americas Genetic Program – Research and Development in Americas Genetic Program

Pac Roots intends to deploy a global R&D program focused on rigorously testing elite strains in various rich agricultural regions throughout the Americas, with a goal of mass selection to achieve the utmost environmental resilience while achieving notable quality and yields. From seed to software, collection data, proprietary techniques and custom nutrient formulas, Pac Roots and Phenome will provide the specific knowledge to cultivators in different climates in order to achieve optimal yields for THC, CBD, CBG and other unique cannabinoids. R&D from global testing programs situated throughout the Americas will allow the partnership to deploy and stress test a range of suitable cultivars in the world’s lowest cost outdoor growing regions.

The company expects an industry shift in 2020 from the COVID-19 global pandemic. The ‘new normal’ will bring more focus on efficiencies and optimal yields to deliver a cost effective, high quality product to the end user. There has been much to be learnt from the inefficiencies in the cannabis industry in recent years, which have been detrimental to the credibility of the sector. Pac Roots is well positioned to enter the scene and take advantage of the deficiencies, reinforcing the notion that genetics and flawless growing techniques are paramount to success. Genetics and systems innovation may be the most overlooked components when comparing cannabis to other established agricultural crops. Pac Roots plans to invest into cannabis R&D to ensure a solid foundation is built that will be used by cannabis farmers worldwide.

Through its RAD Americas Development and Innovation, Pac Roots is focused on:

  • Deploying one of the largest live genetic libraries in Canada, diversified for high yield output and unique climates
  • Continued stress testing for indoor, high yield, THC and medicinal genetics
  • Continued stress testing for outdoor, high yield, THC and medicinal genetics
  • Exotic, genetic cloning for the luxury, high margin, cannabis flower market
  • Psychoactive/medicinal ratio testing for effect and
  • Unique Cannabinoid and terpene elevation and isolation.

Through its RAD Americas Field Testing System, the company is focused on:

  • Global testing in different microclimates to assess genetic and complete systems for optimal yields
  • Data collection, testing and optimization to prove process for commercial implementation and
  • High quality yield testing for THC, CBD, CBG and other unique medicinal cannabinoids.

Lake Country Cultivation Facility near Kelowna, British Columbia

Pac Roots is in the process of completing its 20,000 square foot cultivation facility in Lake Country, British Columbia. The facility is expected to feature approximately 7,600 square feet of cultivation space that will enable the company to cycle through its line of high-grade cultivars. Pac Roots plans to submit a video evidence package of the facility build under Health Canada’s Cannabis Tracking and Licensing System, and the company expects to acquire its cultivation license in the fourth quarter of 2020.

Lake Country is a municipality located just outside of Kelowna in the Okanagan region of British Columbia. For decades, the region’s favorable growing climate has made it a hub for cannabis cultivation. As the Canadian legal cannabis industry ramps up, the Okanagan region is attracting attention from dozens of cannabis companies, including some of the industry’s biggest names. The region’s strong agricultural history has left it rich with experienced agricultural workers and an abundance of Agricultural Land Reserve (ALR) property.

Management Team

Patrick Elliott, MSC, MBA, President and CEO of Pac Roots Cannabis, is also the President & CEO of Lexore Capital Corp., a private resource and cannabis investment company, as well as Phenome One Corp., a full-service cannabis farming company focused on elite strain selective breeding. Elliott brings over 15 years of corporate finance, mineral exploration and financial markets experience to the Pac Roots team. He is a graduate of the University of Western Ontario in geology and holds an MSc. in mineral economics and an MBA from Curtin University of Technology in Perth, Australia. Elliott specializes in economic resource evaluation, financial modeling, CAPEX estimation, corporate development and finance. Combined with his technical knowledge, Elliott has a wealth of contacts in the financial sector.

Marc Geen, Founder and Strategic Operations Advisor, is a fourth-generation British Columbia farmer who has been active in the legal medical marijuana industry for more than 10 years – consulting on, complying with, and participating in the MMAR, MMPR and ACMPR programs. Prior to co-founding Speakeasy Cannabis Club Ltd., Geen spent 14 years as Head of Operations for Kettle Mountain Ginseng Ltd., one of North America’s largest ginseng producers. With the experience gleaned from a long career in large scale commercial farming, Geen has been able to apply many cost-effective farming practices to the outdoor, indoor and greenhouse cultivation of cannabis. Geen is also the co-creator of a full line of cannabis extract products designed under ACMPR regulations.

Matt McGill, Director, has a strong background in both commercial and residential real estate and has played a major role in many development projects. McGill, through McGill Realty, has established a tremendous commercial and residential outfit servicing British Columbia’s Fraser Valley and the lower mainland. McGill is skilled at crafting strategic financing options for corporations and has a substantial network of retail and institutional clients.

Chad Clelland, Director, has experience in the sector dating back to 2009, when he purchased Medicalmarijuana.ca, which became an information portal for thousands of patients, doctors and growers. Through this company, he and his team have helped thousands of Canadians find legal, safe medication. His team also consulted, designed and submitted dozens of applications to the government under the MMPR, ACMPR and Cannabis Act. In 2011, Clelland co-founded Greenleaf Medical Clinic, which is now recognized as a training facility by the University of British Columbia and offers preceptorships to physicians, nurse practitioners and pharmacists. He also co-founded Folium Life Science in 2013, an approved Canadian Licensed Producer. His roles in these organizations have included Chief Operating Officer, head of security, alternate master grower and alternate responsible person in charge.

Josh Bromley, Senior Cultivation Strategist, is a second-generation farmer with over two decades of experience farming, breeding, cultivating and selecting unique cultivars for the medical community. He is an expert in plant science and possesses a comprehensive knowledge of cultivars and a mastery of medicinal implementation. Bromley has developed proprietary farming systems, as well as low cost/high output nutrient systems. Through thoughtful design and engineering, he has been able to consistently show improvements in crop yields, pathogen resiliency and quality.

Pac Roots Cannabis Corp. (PACR), closed Tuesday's trading session at $8.96, even for the day, on 57,200 volume with 4 trades. The average volume for the last 3 months is 11,610 and the stock's 52-week low/high is $4.54500007/$9.22999954.

Recent News

Net Element (NASDAQ: NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element (NETE).

Net Element (NASDAQ: NETE) was featured today in a publication from Green Car Stocks, examining how, with global warming on the rise, considerable interest has been showsn in switching to green, renewable energy. Battery-powered vehicles have emerged as the perfect replacement for fossil-fuel-powered vehicles. These vehicles are powered by rechargeable batteries and produce minimal emissions, making them the perfect vehicle for a net-zero economy.

On June 15, 2020, Net Element announced its entry into a binding letter of intent to merge with privately-held Mullen Technologies Inc., a Southern California-based electric vehicle company, in a stock-for-stock reverse merger in which Mullen’s stockholders will receive the majority of the outstanding stock in the post-merger company. The proposed merger is currently pending the execution of a definitive agreement, shareholder vote and regulatory approval.

Net Element Inc. (NASDAQ: NETE) is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce and mobile devices. The company operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. The company’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

Net Element has also launched a blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element chairman and CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

  • Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
  • Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
  • Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked on Deloitte’s Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in both 2017 and 2018, during which the company grew 190 percent and 183 percent, respectively. The company credits its progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

Net Element was also listed among South Florida Business Journal’s 2016 fastest growing technology companies.

Leveraging its suite of application performing interfaces (APIs) and connectors, Net Element powers commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Leading this innovation is chairman and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jeffrey Ginsburg, CPA, and Steven Wolberg, the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations like Aptito to e-commerce and retail payment transaction processing brands like Payonline and Unified Payments, Net Element is transforming the online and mobile experience.

Net Element (NETE), closed Tuesday's trading session at $6.31, off by 3.2209%, on 281,128 volume with 1,944 trades. The average volume for the last 3 months is 1,328,603 and the stock's 52-week low/high is $1.472/$20.0783996.

Recent News

DarioHealth Corp. (NASDAQ: DRIO)

The QualityStocks Daily Newsletter would like to spotlight DarioHealth Corp. (DRIO).

DarioHealth Corp. (NASDAQ: DRIO) was featured today in a publication from BioMedWire, examining how it is commonly known that Apple is working on bettering its offerings in the wellness and health category. The company was recently awarded a patent that indicates that the firm is taking its approach into health a step further with a new invention: biomedical smart glasses.

New York and Israel-based DarioHealth Corp. (NASDAQ: DRIO) leads global digital therapeutics (DTx) with its popular, smartphone-centered personalized chronic illness management software-as-a-service (SaaS). The company’s strategic advantages include:

  • AI-powered digital solutions that drive durable behavior change in chronic disease patients, and
  • Personalized user experience at scale to make behavior change the path of least resistance.

Approximately $3 trillion in annual U.S. costs associated with chronic illnesses like diabetes, hypertension and obesity are largely preventable with behavioral therapies. Formerly limited to periodic office visits, these therapies can now scale to millions with tech-enabled, continual and remote health monitoring, as well as AI-driven digital and live coaching. This is all possible while still maintaining the personalization required for success in reducing illness and its related effects and costs.

Roughly 51,000 active, paying users manage their health with Dario’s platform that combines smartphone-connected vitals measurement, remote patient monitoring (RPM), lifestyle management tools, and AI-driven and human coaching to deliver improved clinical outcomes.

Among the most downloaded medical apps, the Dario platform is rated at 4.9 stars on the Apple App Store and features 11,000 reviews, along with a Net Promoter Score (a measurement of consumers’ willingness to recommend the product to others) that’s the highest in its field.

Company Strategy

Clinical studies demonstrate Dario’s direct improvement on users’ health measures like H1AC scores (diabetes) and blood pressure (hypertension).

Patient engagement in therapies leads to health success. Dario’s platform centers on continual maximization of patient engagement through personalization, including ‘nudges’ and live, AI-generated responses to health measures provided by Dario’s smartphone-connected medical devices.

Proprietary data analysis provides valuable insights that not only improve health care providers’ medical capabilities but, through artificial intelligence, encourage patients to take evidence-based and highly personalized preventative measures that reduce risk, emergency room visits and preventable hospitalization.

Dario is now deploying its successful B2C platform in B2B2C, targeting employers and health plans with competitive advantages in cost, software and hardware.

The company estimates an annual addressable U.S. market of $72 billion, only 1% of which has been penetrated with digital therapeutics.

The strategic transition to B2B2C (from exclusively B2B) is intended to accelerate revenue growth by reducing Dario’s cost per acquisition per user and expanding margins.

Dario’s commitment to aggressive growth is also shown by its appointment of a new president, chief medical officer and head of sales for North America, all from a highflyer behavioral health company.

Key growth drivers planned include expansion of the company’s paying B2C subscriber base; lateral expansion into other chronic conditions that overlap with its core diabetes populations, such as hypertension, obesity and depression; and increased B2B2C penetration.

Financial Highlights

The company plans to leverage a massive opportunity for growth, with a global addressable market for digital therapeutics of roughly $108 billion. In the U.S. alone, that number is estimated at $72 billion, and only about 1% of that market has been penetrated.

Dario’s strategic transition to an SaaS membership business model increased gross profit by 87% in Q1 2020, as compared to the prior year. Membership revenue increased from 27.1% to 46.7% in the same period. The company is seeing improved operating efficiencies as it shifts focus to the B2B2C business model, and it expects average revenue per user per month (ARPU), which was $6 and $25 in 2019 and 2020, respectively, to reach $70.

Value to Consumers and Businesses

Dario continually evaluates and optimizes the value and return its platform delivers to consumers and businesses.

Consumers seeking to understand how their everyday behavior impacts their personal health and chronic conditions benefit from actionable feedback on how to improve health and better collaborate with health care providers.

Businesses looking to increase employee satisfaction, loyalty and productivity with fewer health-related absences take advantage of Dario’s services for employers.

Health care providers improve patient compliance using the platform’s interactive services that allow for greater monitoring, which improve engagement with patients at the right times and with the right treatments.

Health plans can leverage DarioHealth’s solutions to improve patient outcomes and lower costs.

Recent Studies

The company recently presented the results of two new studies at the American Diabetes Association’s 80th Scientific Sessions, which showed sustained improvements in blood glucose levels and blood pressure among users of its digital therapeutic platform for chronic diseases. The results of these two studies demonstrate that the use of Dario’s therapeutic platform promotes behavioral modification, enhanced individual engagement and improved clinical outcomes.

Remote Patient Monitoring (RPM) Agreements

The Centers for Medicare & Medicaid Services recently approved RPM codes for Medicare patients, which enables physicians to bill for between-visit patient care.

This simplifies implementation of the company’s open and scalable AI-driven platform and further supports transition to the company’s high-margin, recurring SaaS model targeting B2B2C revenue channels.

Emergency COVID-19 FDA Guidelines Allow Self-Test Blood Glucose Meters

In an effort to preserve personal protective equipment (PPE) and reduce contact between health care providers and patients in hospital settings due to COVID-19, the U.S. Food and Drug Administration (FDA) has recognized that home-use blood glucose meters, including Dario’s smartphone-connected metering device, may be used by patients with diabetes who are hospitalized due to COVID-19 to check their own blood glucose levels and provide the readings to the health care personnel caring for them.

As a result, hospitals can now allow patients to self-test using their Dario blood glucose testing strips and smartphone-connected devices, or hospitals can issue patients Dario devices upon admission for COVID-19-related conditions.

Irregularities in blood glucose levels are suspected as a factor in the increased severity of potentially deadly COVID-19 complications. As such, a high priority is being placed on stabilization of patients’ blood glucose levels.

Awards and Recognition

DarioHealth’s Blood Glucose Monitoring System was voted as the ‘Best Glucometer for Data Management’ by Top Ten Reviews. Jeph Preece, senior editor at Top Ten Reviews, said, “The Dario app is the best data management system that I’ve seen. Compared to apps by popular brands, Dario’s system looks and feels like it’s years ahead of the curve.”

‘The Global Digital Health 100’, an annual award sponsored by the reputable Journal of Health, recognized DarioHealth as a leader among health technology companies demonstrating the greatest potential to change the way that health care is delivered.

DarioHealth Corp. (DRIO), closed Tuesday's trading session at $12.55, up 1.0467%, on 51,644 volume with 559 trades. The average volume for the last 3 months is 271,483 and the stock's 52-week low/high is $3.01999998/$22.4899005.

Recent News

Trxade Group Inc. (NASDAQ: MEDS)

The QualityStocks Daily Newsletter would like to spotlight Trxade Group Inc. (NASDAQ: MEDS).

Trxade Group (NASDAQ: MEDS), an integrated drug procurement, delivery and health-care platform, will release financial results for the third quarter ended September 30, 2020, after market close on Monday, October 26, 2020. According to the update, Trxade management will host a conference call to discuss the results at 5:00 p.m. Eastern Time on Monday, October 26, 2020. The call will conclude with Q&A from participants. Interested parties may join the call by dialing 1-877-425-9470 (U.S.) or 1-201-389-0878 (International) and entering conference ID: 13711397. To register for the event, visit the following webcast link: https://ibn.fm/E4I4K. Attendees are asked to dial in at least 10 minutes prior to the call to ensure timely participation. To view the full press release, visit http://ibn.fm/1Wo4Z

Trxade Group Inc. (NASDAQ: MEDS) is an integrated pharmaceutical services company that offers a unique combination of a web-based purchasing platform (www.trxade.com) for transactions between independent pharmacists and drug distributors (B2B); a network of pharmacies with E-Hub software; a mail order pharmacy; and warehouse and drug delivery services. This synergistic combination of product offerings and superior data analytics is poised to benefit all stakeholders and consumers within the pharmaceutical industry.

Trxade will leverage and scale its fully integrated model to execute the following growth strategies:

  • Increase share of pharmacist drug purchasing
  • Additional SKUs and expand product breath
  • Partner with Specialty and International Mfg.
  • Expand mail order licenses to all 50 states
  • Scale Delivmeds for consumer delivery nationwide
  • Integration with telemedicine
  • M&A Opportunities within drug value chain

Founded in 2010 and headquartered in Tampa, Florida, Trxade’s overarching corporate strategy is to penetrate the existing retail independent pharmacy marketplace and diversify the company’s pharmaceutical mix with additional specialty and acute care products. Trxade is advancing on this mission by focusing on three key niches in the health care market.

Business-to-Business (B2B)

The $330 billion U.S. pharmaceutical industry is comprised of more than 65,000 pharmacy facilities and 1,500 state-licensed suppliers. Roughly 24,000 of these facilities are independent pharmacies, which collectively spend approximately $93 billion a year on branded and generic drugs.

Trxade targets these independent pharmacies, leveraging a robust, “E-Bay/Kayak-like” technology platform with optimum buyer/seller pricing algorithms, product availability, and predictive data analytics features.

Trxade currently serves and transacts with more than one-third (10,250) of these independent pharmacies and facilitates over $10 million of drug purchases a month!

Consumer

Trxade also targets the “consumer side” of the pharmaceutical industry, aiming to lower prescription drug costs by attacking the inefficient value chain; offering drug price transparency and efficient buying; and, delivering drugs DIRECT to independent pharmacists and consumers.

The company operates a full-service mail order pharmacy for U.S. consumers, as well as a mobile app called “Delivmeds” (http://www.delivmeds.com) which enables SAME DAY home delivery of dispensed prescriptions.

Retail

Trxade’s Managed Services Organization (“TrxadeMSO”) enables its member independent retail pharmacies to get patients, process orders, and deliver or ship prescriptions to patients. TrxadeMSO provides access to encompassing network of pharmacies through the E-Hub software, allowing for timely and comprehensive medication fulfillment.

These offerings ensure the best-suited pharmacy receives the patient’s information, thereby ensuring appropriate medication coverage based on the patient’s location, payor coverage, and medication access/inventory. This will save the clinicians and their staff time as they benefit from efficiency and enhanced workflow management in script processing and fulfillment.

Health Care Market

The U.S. health care market currently hovers near $4 trillion and is expected to grow as the general population ages. This growth will have greater impact on consumers as out-of-pocket expenses also rise. Additionally, drug costs are paced to increase faster than the overall health care and well above inflation.

Drug pricing is variable, and reimbursement is squeezing profits. This provides significant opportunity for the Trxade model of price visibility and profit optimization.

Trxade’s fair online market platform targets the nation’s retail community and independent pharmacies, of which there are approximately 24,000 nationwide. TRxADE has found that independent pharmacies, in order to be cost-effective, often operate with minimal staff and conduct up-to-the minute price checks. The TRxADE S2P platform gives these pharmacists the ability to easily compare the price of drugs offered by various suppliers and select the most favorable deals, saving money by taking advantage of best purchase pricing.

TRxADE’s programs include:

  • TRxADE Exchange, which opens and widens the distribution channel to the retail, community pharmacy. A purchasing pharmacy can view products from manufacturers, buying groups, and wholesalers on a real-time and continuous basis. This approach significantly enhances the competitive spirit of the exchange where the lowest price exists for each product at any given point in time. TRxADE has become a competitive tool for all progressive entities and is recognized for its easy searching of hard-to-find generic pharmaceuticals at substantially reduced prices.  
  • RX Guru™ is an industry-leading price prediction model that integrates product shortage insight into pharmacy acquisition benchmarks (“PAC”) to ascertain trends and pricing variances that result in significant purchasing opportunities. RX Guru affords members the opportunity to continuously benefit from real price purchasing opportunities that are concealed from the rest of the industry. 
  • Product Shortage Database – TRxADE maintains the most comprehensive retail, specialty and acute care pharmaceutical product shortage database in the country. Other industry competitors mainly restrict their efforts to specialty and acute care product shortages and narrowly research oral generic products. TRxADE’s advanced prediction tools help members source those hard-to-find products at affordable costs in a timely and easy-to-search process. 

Management Team 

Trxade’s management team is rich in expertise within the pharmaceutical supply chain and is supported by a base of advisors and contractors who are experts in related fields of the pharmaceutical sector.

Suren Ajjarapu – Chairman of the Board, Chief Executive Officer and Secretary
Suren Ajjarapu has served as Trxade’s chairman of the board, CEO and secretary since 2014, and as the chairman of the board, chief executive officer and secretary of Trxade Nevada since its inception. Ajjarapu also serves as a chairman of the board for Feeder Creek Group Inc., since March 2018. Ajjarapu formerly was a founder, CEO and chairman of Sansur Renewable Energy Inc., a company involved in developing wind power sites in the Midwest, United States; a founder, president and director of Aemetis Inc., a biofuels company (AMTX.OB); a founder, chairman and CEO of International Biofuels, a subsidiary of Aemetis Inc.; and a co-founder, COO, and director at Global Information Technology Inc., an IT outsourcing and systems design company. Ajjarapu holds an M.S. in environmental engineering from South Dakota State University, Brookings, South Dakota, and an MBA from the University of South Florida, specializing in international finance and management. Ajjarapu is also a graduate of the Venture Capital and Private Equity program at Harvard University.

Prashant Patel – Director, President and Chief Operating Officer
Prashant Patel has served as Trxade’s full-time president and COO, and as a director since the company’s acquisition of Trxade Nevada in 2014, and as the COO and president and as a director of Trxade Nevada since its inception. He has been a president and member of the board of Trxade since August 2010. Patel is a registered pharmacist and pharmaceutical consultant with over 10 years of experience in retail pharmacy and pharmaceutical logistics. He is the founder of several pharmacies in the Tampa Bay area, in Florida. Since 2008, Patel has been managing member of the APAA LLC pharmacy. Since 2007, Patel has been a vice president of Holiday Pharmacy Inc. Patel graduated from Nottingham University School of Pharmacy and practiced in the United Kingdom before obtaining his masters in Transport, Trade and Finance from Cass Business School, City University, UK.

 

Trxade Group Inc. (NASDAQ: MEDS), closed Tuesday's trading session at $5.05, off by 18.5484%, on 1,318,115 volume with 9,213 trades. The average volume for the last 3 months is 80,201 and the stock's 52-week low/high is $4.01000022/$11.6000003.

Recent News

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Predictive Oncology (NASDAQ: POAI) CEO Carl Schwartz was featured in a recent NetworkNewsWire (“NNW”) audio interview. During the interview, Schwartz provided updates on the company’s subsidiaries, noted recent company milestones and outlined near-term goals. POAI, a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has four wholly owned subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. To listen to the full interview, visit http://ibn.fm/xQQwT. To view the full press release, visit http://ibn.fm/MEFLq.

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

  • A database of clinically validated historical and outcome data from patient tumors
  • An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
  • A “smart” patient-derived tumor profiling platform
  • An in-house bioinformatics artificial intelligence (AI) platform
  • A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
  • An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Tuesday's trading session at $0.7875, off by 2.1009%, on 313,069 volume with 521 trades. The average volume for the last 3 months is 1,267,658 and the stock's 52-week low/high is $0.730499982/$5.38999986.

Recent News

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

Sharing Services Global (OTCQB: SHRG), a diversified holding company specializing in the health and wellness direct-selling industry, was featured in a recent industry report published by an investment banking and business development firm Transformation Capital as one of the fastest-growing small-cap companies in the space (https://nnw.fm/XhXSO).

Sharing Services Global Corporation (SHRG), formerly Sharing Services Inc., is a diversified company dedicated to maximizing shareholder value, operating through two primary subsidiaries: Elepreneurs Holdings, a direct-selling company, and Elevacity Holdings, a products company. Headquartered in Plano, Texas, SHRG markets and distributes Elevate-branded health and wellness products through an independent sales force of distributors called Elepreneurs.

Proprietary Products

SHRG’s current exclusive Elevate product offerings are marketed under the Elevacity brand, so named to signify the company’s commitment to elevating lives.

The Elevate health and wellness product line consists of nutraceutical products that SHRG refers to as D.O.S.E., which stands for dopamine, oxytocin, serotonin and endorphins – all of which are key hormones proven to promote happiness and well-being.

Elevacity brand products are carefully formulated, chosen and designed to support a single objective: elevate the happiness and well-being of the consumer.

Global Network of Elepreneurs

Elevacity products are shared and sold by a growing international network of home-based entrepreneurs, called Elepreneurs, operated by Elepreneurs Holdings. This SHRG subsidiary provides basic and advanced programs for both new and experienced entrepreneurs who are focusing on their direct-sales careers.

SHRG’s high-performing independent sales force follows the company’s Blue Ocean selling strategy, an approach that encourages individuals to seek new markets, lead, and to “stop competing and start creating.” The Blue Ocean strategy is based on the book, “Blue Ocean Strategy,” written by Professor Renée Mauborgne, who notes that “the lesson here is that the best defense is offense, and the best offense… is to make a blue ocean shift and create your own blue ocean.”

Following this selling strategy, SHRG’s Elepreneurs are taught that, rather than competing directly in a competitive, direct-selling market, they should focus on making competitors irrelevant and succeeding in an uncontested marketplace.

In addition, SHRG’s Elepreneurs use the interactive, video-based VERB sales-marketing platform developed by Verb Technology Company Inc. The app utilizes proprietary interactive video data collection and analysis technology and provides next-generation customer relationship management, lead generation, and video marketing software applications.

Continued Momentum as Industry Leader

These selling strategies have resulted in sharp and consistent revenue gains. In the company’s 10-Q filed with the SEC for the three months ended Oct. 31, 2019, SHRG reported sales of $38.8 million for fiscal Q2 2019, an increase of 116% over sales of $17.9 million reported for the comparable quarter of 2018. Consolidated gross profit jumped by $16.2 million to $27.4 million for the same period compared to Q2 2018.

SHRG’s consolidated operating earnings were $3.9 million in the fiscal quarter ended Oct. 31, 2019, compared to $866,802 for the comparable period the prior year. Consolidated gross margin also grew 70.9% for the three months ended Oct. 31, 2019, compared to 62.2% the prior year.

These numbers are continuing a trend established over the past two years. In fiscal Q1 2019, SHRG achieved revenues of $35.4 million, more than double that of the comparable period in 2018. Even earlier, the company reported sales of $85.9 million for fiscal year ended April 30, 2019. This represents a nine-fold increase, or $77.5 million jump, over the company’s revenues of $8.4 million the prior year.

These numbers bring SHRG’s sales revenues since December 2017 — when the company’s Elevate product line was released — to an impressive cumulative total of $169 million.

Preparing for Success

SHRG is well prepared to continue and accommodate for this growth. The company recently expanded its corporate footprint by moving to a 10,000-square-foot facility in Plano, Texas, that offers ample room to expand as the company grows and flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

In addition, the company has a seasoned, expert leadership team in place, led by John “JT” Thatch. Thatch was appointed president and CEO of SHRG in March 2018, bringing to the company his expertise obtained from successfully starting, owning and operating several businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist SHRG as the company aims to expand and increase revenues.

Contact
469.304.9400 x 201
Info@SHRGinc.com
http://www.SHRGinc.com

Sharing Services Global Corporation (SHRG), closed Tuesday's trading session at $0.20, off by 12.2807%, on 419,886 volume with 71 trades. The average volume for the last 3 months is 333,934 and the stock's 52-week low/high is $0.0215/$0.730000019.

Recent News

Sugarmade, Inc. (SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (SGMD).

Sugarmade (OTCQB: SGMD), a leading, multidivisional/multiproduct/multisector supply company, recently entered into an agreement to lease five acres of land in Northern California (https://cnw.fm/adC1Q). SGMD intends to use the property, which is zoned for cannabis cultivation, to establish and operate licensed production with the capacity to produce as much as 3.6 million grams of high-quality cannabis flower per year. To view the full article, visit: https://cnw.fm/fQM4c

Sugarmade, Inc. (SGMD) is headquartered in Monrovia, California, where the company recognizes new opportunities in the cannabis delivery space and in the market for supplies to the quick-service restaurant industry – both of which have fast-changing dynamics due to the recent outbreak of coronavirus in the United States.

The Coronavirus Cannabis Boom Market

Retailers across the nation are closing their doors and curtailing operations due to the coronavirus pandemic, inherently pinching sales. In the California cannabis sector, however, business has never been better – especially relative to home delivery.

California’s cannabis industry continues to operate, and media reports reveal booming cannabis sales as the state’s citizens stay home to wait out current events. The Los Angeles Times recently published the headline, “Marijuana Sales on Fire amid Virus Outbreak; New York Post “Cannabis sales hit new highs”; USA Today “American Stock Up on Pot” Fox News “California marijuana sales surge”; and ABC News Cannabis Shops thrive in coronavirus pandemic.

The state of California benefits from the ultra-high taxes paid by the highly regulated cannabis industry, and has thus deemed cannabis companies as “essential” businesses, allowing for full operations to continue. While pot shops are seeing strong foot traffic, the real growth action is in-home delivery as consumers seek to embrace social distancing. Many delivery operators are reporting difficulty in meeting demand with sales growth of up to 10% sequentially each week. It is certainly a boom time for the industry.

Sugarmade Growth Strategy

Recognizing new investment and operational opportunities within California’s cannabis market, Sugarmade is strategizing to take advantage of opportunity specifically in delivery services (non-storefront retailer), manufacturing via co-branding, and selective genetic cultivation. The company is taking a highly selective approach, targeting only the best of these opportunities for company growth.

In line with this strategy is northern California delivery service Budcars, in which Sugarmade owns a 40% interest and an option to gain a controlling interest. Budcars connects consumers with premium products sourced from top-tier farms and extractors, offering a curated menu of fully compliant cannabis products. The company maintains a competitive advantage by sourcing premium cannabis offerings and same-day delivery. In addition to maintaining its own cars, California licenses, and fulfillment center, Budcar orders its premium products in bulk at lower prices, enabling the company to rein in costs and maintain competitive pricing for its customers. Currently serving major communities within the metropolitan area of Sacramento, Budcars plans to continue the expansion of the company’s delivery reach.

Sugarmade plans to continue its expansion into burgeoning new sectors of the cannabis market through the following avenues:

  • Geographic expansion of Budcars delivery scope
  • New delivery geographies
  • Cannabis cultivation as a key component of a hybrid vertical integration strategy
  • Product technology expansion—including products containing exotic and lesser-known cannabinoids

 

Diversified Portfolio

Sugarmade has positive market exposure to cannabis delivery, as well as to the restaurant industry, at a time when these businesses are being force to move toward take-out and delivery models in order to survive.

The company has various business operations in diverse marketplaces, including food, safe packaging and sanitary supplies for various industries, and agricultural supplies. Sugarmade entered the industrial hemp and CBD space by investing in Hempistry, Inc., a privately held Nevada corporation. Hempistry began planting an ultra-high cannabidiol (CBD) industrial hemp strain on a land option it holds on 5,000 acres of prime Kentucky farmland. The strain of industrial hemp being grown by Hempistry is ultra-rich in CBD but contains less than 0.3% of THC, the psychoactive ingredient found in cannabis.

CarryOutSupplies.com, the leader in paper and plastic take-out supplies, serves nationwide customers by offering a wide array of high-quality products that are cost-efficient, custom-made and delivered on time. This business unit currently serves 2,000 quick service restaurants, garnering from 30%-40% of the market share. Sugarmade plans to expand operations via the addition of market share and the introduction of new product offerings.

Market Opportunity

There is little doubt among industry participants, and recently confirmed by Forbes, that California is the single largest cannabis market in the world. The state is expected to produce more than $3.5 billion in cannabis sales during 2020, with growth topping 23% annually. The global industrial hemp market size was estimated at $4.71 billion in 2019 and is expected to register a revenue-based CAGR of 15.8% over the forecast period of 2016-2027, according to Grandview Research. Market growth drivers include the 2018 Farm Bill and society’s increasing knowledge of the benefits of hemp products.

Overall industry growth is great, but specific vertical sector growth is even better. Cannabis delivery is clearly the fastest growing sector of the marketplace and with coronavirus fears the already robust growth rate has accelerated.

Sugarmade seems to be in the right industry at the right time in history.

Management

CEO Jimmy Chan is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, and international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick-service restaurant industry, which merged with Sugarmade in 2014.

Dedicated to getting the highest caliber of THC and CBD to its customers’ door, the company’s priority is to ensure that they receive the highest quality cannabis product free from logistical hassles. Sugarmade specializes in growing and acquiring innovative brands to maximize value for company employees, shareholders and other stakeholders. Sugarmade believes its future is very bright as the company expands operations within the cultivation sector and rapidly increases its revenue base.

Sugarmade, Inc. (SGMD), closed Tuesday's trading session at $0.0016, up 14.2857%, on 14,396,241 volume with 00 trades. The average volume for the last 3 months is 000,000 and the stock's 52-week low/high is $0.001249999/$0.020439999.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.